Pad3 activity modulators and their use in treating immune-driven conditions
Patent Information
- Application Number
- PCT/US2026/017824
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-03-05
- Filing Date
- 2026-03-05
- Publication Date
- 2026-11-12
AI Technical Summary
Existing immune-driven conditions, such as autoimmune diseases and adverse immune responses during pregnancy, are not effectively managed by current therapies, as they disrupt the balance between endogenous proteases and protease inhibitors, leading to undesired immune responses.
The use of PAD3 protein inhibitors, specifically compounds like CAY10727, to modulate the activity of inter-alpha-trypsin inhibitor H4 isoform (ITIH4) and regulate immune responses, thereby suppressing adverse immunoenhancement or enhancing immunosuppression as needed.
PAD3 inhibitors effectively manage immune-driven conditions by restoring the balance of immune responses, reducing inflammation and preventing tissue damage, while promoting healthy pregnancy outcomes by maintaining self-tolerance.
Smart Images

Figure US2026017824_12112026_PF_FP_ABST
Abstract
Description
[0001] PATENT
[0002] ATTORNEY DOCKET NO.: 51523-007WO2
[0003] PAD3 ACTIVITY MODULATORS AND THEIR USE IN TREATING IMMUNE-DRIVEN CONDITIONS
[0004] Background of the Invention
[0005] The interaction between endogenous proteases and protease inhibitors plays a critical role in regulating the immune system and maintaining self-tolerance. This interaction is especially crucial in regulating the immune system and maintaining self-tolerance during pregnancy. This type of regulation ensures the mother’s immune system can protect against infections while tolerating the semi-allogeneic fetus. Some of these regulated immune responses have been attributed to the activity of the plasma protein, inter-alpha-trypsin inhibitor H4 isoform (ITIH4) . As such, the ability to modulate ITIH4 activity is of therapeutic value for immune-driven conditions.
[0006] Summary of the Invention
[0007] The present invention is directed to PAD3 protein and its inhibitors, and their use in modulating ITIH4 activity for treating immune-driven conditions, i.e., conditions characterized by adverse immunoenhancement.
[0008] In one aspect, the invention is a method of suppressing the immune response in a subject with an immune-driven condition, the method comprising administering a PAD3 selective inhibitor of formula (I):
[0009]
[0010] or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a PAD3 selective inhibitor of formula (I),
[0011] wherein,
[0012] n is 0, 1 , 2, 3, or 4;
[0013] X is Cl or F;
[0014]
[0015] Y is H, C1-C3 alkyl, or R2, where = is either a single bond or a double bond; each Z1, Z2, and Z3are independently CR1, NR1, O,
[0016]
[0017] ,
[0018] each R1is independently H, C1-C3 alkyl, halogen, -NHC(O)-R4, -C(O)NH2, =0, optionally substituted 6- to 9 -membered C5-C7 heteroaryl, or two R1together with the atoms to which they are bound form an optionally substituted 5- to 6-memeberred C2-C5 heterocyclyl or optionally substituted 5- to 6-membered C2-C5 heteroaryl;
[0019] R2is H, C1-C3 alkyl, O, or Ce aryl;
[0020] R3is H, C1-C3 alkyl, C6aryl,
[0021]
[0022] R2and R3together with the atoms to which they are attached combine to form a Ce aryl or a 6- to 10-membered C5-C7 heteroaryl;PATENT
[0023] ATTORNEY DOCKET NO.: 51523-007WO2
[0024]
[0025] each R5is independently -O-(Ci-C3 alkyl), -CO2H, or halogen; or
[0026] two R5together with the atoms to which they are attached form an optionally substituted 5- to 6-membered heterocyclyl;
[0027] L is bond or -C(O)NH-; and
[0028] each optionally substituted group is optionally substituted with 1 , 2, 3, or 4 substituents independently selected from a group consisting of: C1-C3 alkyl, -O-(Ci-C3 alkyl), halogen, and =0. In another aspect, the invention is a method of suppressing the immune response in a subject with an immune-driven condition, the method comprising administering a PAD3 selective inhibitor of formula (la):
[0029]
[0030] or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a PAD3 selective inhibitor of formula (I),
[0031] wherein,
[0032] n is 0, 1 , 2, 3, or 4;
[0033]
[0034] Y is H, C1-C3 alkyl, or R2, where = is either a single bond or a double bond; each Z1, Z2, and Z3are independently CR1, NR1, O,
[0035]
[0036] ,
[0037] each R1is independently H, C1-C3 alkyl (e.g., methyl, ethyl, propyl, isopropyl), halogen (e.g., F, CL, Br, I), -NHC(O)-R4, -C(O)NH2, =0, 6- to 9 -membered C5-C7 heteroaryl, or two R1together with the atoms to which they are bound form an optionally substituted 5- to 6-memeberred C2-C5 heterocyclyl or optionally substituted 5- to 6-membered C2-C5 heteroaryl;
[0038] enyl);
[0039]
[0040] R2and R3together with the atoms to which they are attached combine to form a Ce aryl or a 6- to 10-membered C5-C7 heteroaryl;
[0041]
[0042] each R5is independently -O-(Ci-C3 alkyl) (e.g., methoxy, ethoxy, propoxy, isopropoxy), -CO2H, or halogen;
[0043] L is bond or -C(O)NH-; andPATENT
[0044] ATTORNEY DOCKET NO.: 51523-007WO2
[0045] each optionally substituted group is optionally substituted with 1 , 2, 3, or 4 substituents independently selected from a group consisting of: C1-C3 alkyl, -O-(Ci-C3 alkyl), halogen, and =0. In some embodiments, the PAD3 inhibitor is a compound of formula (II):
[0046]
[0047] or a pharmaceutically acceptable salt thereof, wherein,
[0048] n is 0, 1 , 2, 3, or 4;
[0049] each Z1, Z2, and Z3are independently CR1, NR1, O,
[0050]
[0051] , each R1is independently H, C1-C3 alkyl, =0, halogen, or two R1together with the atoms to which they are bound form an optionally substituted 5- to 6-memeberred C2-C5 heterocyclyl or optionally substituted 5- to 6-membered C2-C5 heteroaryl;
[0052] R2is H, C1-C3 alkyl, or Ce aryl;
[0053]
[0054] each R5is independently -O-(Ci-C3 alkyl) or halogen;
[0055] L is bond or -C(O)NH-; and
[0056] each optionally substituted group is optionally substituted with 1 , 2, 3, or 4 substituents independently selected from a group consisting of: C1-C3 alkyl, -O-(Ci-C3 alkyl), halogen, and =0. In some embodiments, the PAD3 inhibitor is a compound of Table 1 . In specific embodiments, the PAD3 inhibitor is Compound 1 or Compound 2 or Compound 30. In particular embodiments, the PAD3 inhibitor is Compound 1 .
[0057] In another aspect, the invention is a method of suppressing the immune response in a subject with an immune-driven condition, the method comprising administering PAD3 selective inhibitor, wherein the PAD3 selective inhibitor is an antibody, e.g., an anti-PAD3 antibody.
[0058] In some embodiments, the immune-driven condition is inflammation.
[0059] In some embodiments, the immune-driven condition is an autoimmune disease.
[0060] In some embodiments, the immune-driven condition is rheumatoid arthritis.
[0061] In some embodiments, the immune-driven condition is an ocular condition.
[0062] In some embodiments, the immune-driven condition is the rejection of a tissue, cell, graft, or organ transplant from a donor by a recipient human subject in need thereof. In some embodiments, the method includes administering prior to, simultaneously with, or after tissue, cell, graft, or organ transplantation. In some embodiments, the organ transplant is a kidney transplant, a cornea transplant, a bone marrow transplant, a liver transplant, a lung transplant, or a heart transplant.PATENT
[0063] ATTORNEY DOCKET NO.: 51523-007WO2
[0064] In some embodiments, the immune-driven condition is an adverse immune response resulting from administration of a therapeutic agent.
[0065] In another aspect, the invention is a method of improving pregnancy health of a subject, the method includes administering PAD3 inhibitor or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising a PAD3 inhibitor or a pharmaceutically acceptable salt thereof, to the subject in need thereof. In some embodiments, the method includes administering for the entire term of the pregnancy. In some embodiments, the PAD3 inhibitor is a compound of formula (I), formula (la), formula (II), or Table 1 .
[0066] In some embodiments of the aforementioned aspects and embodiments, the pharmaceutical composition including the PAD3 inhibitor or pharmaceutically acceptable salt thereof is administered to the subject in need thereof. In some embodiments, the pharmaceutical composition is formulated for injection, oral administration, or topical administration.
[0067] In another aspect, the invention is a method of enhancing the immune response in a subject with an immune driven condition characterized by immunosuppression, the method includes administering to the subject a therapeutic agent comprising PAD3 protein, or a derivative thereof, or anti-PAD3 antibody.
[0068] In some embodiments, the therapeutic agent includes an amino acid sequence at least 80% identical to PAD3.
[0069] In some embodiments, the immune driven condition is a cancer susceptible to treatment with an immunotherapy. In some embodiments, the cancer is a solid tumor cancer. In some embodiments, the cancer is melanoma, renal cell carcinoma (RCC), colorectal cancer, Metastatic colorectal cancer, Gl malignancies, hepatocellular carcinoma (HOC), HNSCC, Malignant Pleural Mesothelioma, bladder cancer, sarcoma, osteosarcoma, Kaposi’s sarcoma, soft tissue sarcoma, lymphoma, mantle cell, follicular, small lymphocytic, B-cell malignancies, anaplastic large cell lymphoma, Merkel cell carcinoma, MSI-high cancer, gastric cancer, gastroesophageal cancer, cervical cancer, PMBCL, endometrial carcinoma, esophagus cancer, cutaneous squamous-cell carcinoma, breast cancer, Metastatic breast cancer, TMB-high cancer, SCLC, basal cell carcinoma, multiple myeloma, testicular cancer, pancreatic cancer, prostate cancer, ovarian cancer, thyroid cancer, leukemia, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia, acute promyelocytic leukemia (APL), head and neck cancers, lung cancer, non-small cell lung cancer (NSCLC), melanoma, gastrointestinal stromal tumors (GIST), solid tumors, malignant pleural mesothelioma, myelofibrosis, polycythemia vera, Waldenstrom’s macroglobulinemia, glioblastoma, urothelial carcinoma, or myelodysplastic syndromes (MDS).
[0070] In some embodiments, the method includes administering to the subject a combination therapy comprising: a) the therapeutic agent comprising PAD3 protein, or derivative thereof, or an anti-PAD3 antibody, and b) an additional anticancer therapy, each in an amount that together is effective for the treatment of cancer.
[0071] In some embodiments of the aforementioned combination therapy, the additional anticancer therapy is a chemotherapy. In specific embodiments, the chemotherapy is a cytotoxic chemotherapy agent selected from: an alkylating agent, a platinum-based compound, a antimetabolite, a antitumor antibiotic, or a plant alkaloid. In specific embodiments, the cytotoxic chemotherapy agent is selected from a group consisting of: cyclophosphamide (Cytoxan), infosfamide (Ifex), melphalan (Alkeran), chlorambucilPATENT
[0072] ATTORNEY DOCKET NO.: 51523-007WO2
[0073] (Leukeran), bendamustine (Tranda, Bendeka), cisplatin, carboplatin, oxaliplatin (Eloxatin), methotrexate, 5-fluorouracil (5-FU), capecitabine (Xeloda), gemcitabine (Gemzar), pemetrexed (Alimta), cytarabine (ara-C), and 6-mercaptopurine (6-MP), doxorubicin, daunorubicin, epirubicin, bleomycin, and mitomycin (Mutamycin), vincristine, vinblastine, vinorelbind, paclitaxel (Taxol), docetaxel (Taxotere), cabazitaxel (Jevtana), etopside (VP-16), camptothecins, irinotecan (Camptosar), and topotecan (Hycamtin).
[0074] In some embodiments of the aforementioned combination therapy, the additional anticancer therapy is a targeted therapy. In specific embodiments, the targeted therapy is a tyrosine kinase inhibitor (TKI), a monoclonal antibody (mAb), or a antibody-drug conjugate (ADC). In specific embodiments, the targeted therapy is selected from a group consisting of: imatinib (Gleevec), dasatinib (Sprycel), nilotinib (Tasigna), bosutinib (Bosulif), ponatinib (Iclusig), erlotinib (Tarceva), gefitinib (Iressa), afatinib (Gilotrif), osimertinib (Tagrisso), sorafenib (Nexavar), sunitinib (Sutent), pazopanib (Votrient), axitinib (Inlyta), cabozantinib (Cabometyx), dabrafenib (Tafinlar), vemurafenib (Zelboraf), trametinib (Mekinist), cobimetinib (Cotellic), ruxolitinib (Jakafi), ibrutinib (Imbruvica), acalabrutinib (Calquence), idelalisib (Zydelig), duvelisib (Copiktra), rituximab (Rituxan), obinutuzumab (Gazyva), ofatumumab (Arzerra), trastuzumab (Herceptin), pertuzumab (Perjeta), cetuximab (Erbitux), panitumumab (Vectibix), bevacizumab (Avastin), daratumumab (Darzalex), isatuximab (Sarclisa), elotuzumab (Empliciti), inotuzumab ozogamicin (Besponsa), T-DM1 / ado-trastuzumab emtansine (Kadcyla), brentuximab vedotin (Adcetris), sacituzumab govitecan (Trodelvy), and trastuzumab deruxtecan (Enhertu).
[0075] In some embodiments of the aforementioned combination therapy, the additional anticancer therapy is an immunotherapy. In specific embodiments, the immunotherapy is an immune checkpoint inhibitor. In specific embodiments, the immune checkpoint inhibitor is anti-CTLA-4, anti-PD-1 , or anti-PDpL1. In specific embodiments, the immunotherapy is selected from a group consisting of: ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo), atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (bavencio).
[0076] In some embodiments of the aforementioned combination therapy, the additional anticancer therapy is a hormonal therapy. In specific embodiments, the hormonal therapy is a selective estrogen receptor modulator (SERM), an aromatase inhibitor, a selective estrogen receptor degrader (SERD), an anti-androgen, a GnRH (LHRH) agonist, or a GnRH (LHRH) antagonist. In specific embodiments, the hormonal therapy is selected from a group consisting of: tamoxifen, anastrozole (Arimidex), letrozole (Femara), exemestane (Aromasin), fulvestrant (Faslodex), bicalutamide (Casodex), flutamide, nilutamide, enzalutamide (Xtandi), apalutamide (Erleada), darolutamide (Nubeqa), leuprolide (Lupron), goserelin (Zoladex), degarelix (Firmagon), and Relugolix (Orgovyx).
[0077] In some embodiments of the aforementioned combination therapy, the additional anticancer therapy is selected from a group consisting of: lenalidomide (Revlimid), thalidomide (Thalomid), pomalidomide (Pomalyst), bortezomib (Velcade), carfilzomib (Kyprolis), ixazomib (Ninlaro), venetoclax (Venclexta), olaparib (Lynparza), rucaparib (Rubraca), niraparib (Zejula), talazoparib (Talzenna), everolimus (Afinitor), temsirolimus (Torisel), arsenic trioxide (Trisenox), all-trans retinoic acid (ATRA), trabectedin (Yondelis), L-asparaginase (Elspar, Erwinia asparaginase, Pegaspargase), and selinexor (Xpovio).
[0078] In some embodiments, the administration of the combination therapy includes administering the PAD3 therapeutic agent and the additional anticancer therapy simultaneously.PATENT
[0079] ATTORNEY DOCKET NO.: 51523-007WO2
[0080] In some embodiments, the PAD3 therapeutic agent and the additional anticancer therapy are formulated and administered together.
[0081] In some embodiments, the administration of the combination therapy includes administering the PAD3 therapeutic agent and the additional anticancer therapy sequentially.
[0082] In some embodiments, the sequential administration includes administering the PAD3 therapeutic agent and administering the additional anticancer therapy within one week (e.g., 1 week, 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day) of each other.
[0083] In some embodiments, the sequential administration includes administering the PAD3 therapeutic and administering the additional anticancer therapy within 24 hours (e.g., 24 hours, 23, hours, 22, hours, 21 hours, 20 hours, 19 hours, 18 hours, 17 hours, 16 hours, 15 hours, 14 hours, 13 hours, 12 hours, 11 hours, 10 hours, 9 hours, 8 hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, or 1 hours) of each other.
[0084] In some embodiments, the PAD3 therapeutic is administered before the additional anticancer agent. In some embodiments, the PAD3 therapeutic is administered after the additional anticancer agent.
[0085] In some embodiments, the PAD3 therapeutic administered is a gene therapy encoding the PAD3 protein. In some embodiments, the gene therapy is administered to the subject via a viral vector. In some embodiments, the gene therapy that includes a polynucleotide encoding the PAD3 protein is incorporated into recombinant AAV (rAAV) vector.
[0086] Definitions
[0087] The terms, “ITIH4 activation” and “ITIH4 proteolysis” are used interchangeably to refer to the process in which ITIH4 becomes cleaved via proteolysis by human protease and the products can inhibit functions in the immune system.
[0088] The term “administration” refers to the administration of a composition to a subject or system. Administration to an animal subject (e.g., to a human) may be by any appropriate route. For example, in some embodiments, administration may be an orally absorbed pill, or by injection including, but not limited to, intravenous, intramuscular, subcutaneous, and intradermal.
[0089] The term, “autoimmune disorder” refers to an immune-driven condition in which the immune system produces an immune response (for instance, a B cell or a T cell response) against an endogenous antigen, with consequent injury to tissues. This includes, but is not limited to, rheumatoid arthritis, Hashimoto's thyroiditis, pernicious anemia, inflammatory bowel disease (Crohn's disease and ulcerative colitis), psoriasis, renal, pulmonary, hepatic fibroses, Addison's disease, type I diabetes, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, multiple sclerosis, myasthenia gravis, Reiter's syndrome, and Grave's disease.
[0090] The term “alkyl,” as used herein, refers to an acyclic straight or branched chain saturated hydrocarbon group, which, when unsubstituted, has from 1 to 12 carbons, unless otherwise specified. In certain preferred embodiments, unsubstituted alkyl has from 1 to 6 carbons. Alkyl groups are exemplified by methyl; ethyl; n- and iso-propyl; n-, sec-, iso- and tert-butyl; neopentyl, and the like, and may be optionally substituted, valency permitting.
[0091] The term “aryl,” as used herein, represents a mono-, bicyclic, or multicyclic carbocyclic ring system having one or two aromatic rings. Aryl group may include from 6 to 10 carbon atoms, e.g., Ce arylPATENT
[0092] ATTORNEY DOCKET NO.: 51523-007WO2
[0093] such as phenyl. All atoms within an unsubstituted carbocyclic aryl group are carbon atoms. Non-limiting examples of carbocyclic aryl groups include phenyl, naphthyl, 1 ,2-dihydronaphthyl, 1 ,2,3,4-tetrahydronaphthyl, fluorenyl, indanyl, indenyl, etc. The aryl group may be unsubstituted or substituted with one, two, three, four, or five substituents.
[0094] The term “halogen,” as used herein, represents a halogen selected from bromine, chlorine, iodine, and fluorine.
[0095] The term “heteroaryl,” as used herein represents an aromatic monocyclic or bicyclic ring system of 5- to 10-members in which one to six of the members are heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, e.g., a C2-C5 heteroaryl comprising 1 , 2, or 3 nitrogen atoms, for example, imidazolyl, pyrazolyl, triazolyl, pyridinyl, indolyl, etc. The heteroaryl may be substituted, valency permitting with one, two, three, four, or five substituents.
[0096] The term “heterocyclyl,” as used herein, represents a monocyclic ring system of 5- or 6-members in which one, two, three, or four of the members are heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur, e.g., a C2-C5 heterocyclyl comprising 1 , 2, or 3 nitrogen atoms. In some embodiments, “heterocyclyl” as zero, one, or two double bonds. The heterocycyl may be substituted, valency permitting.
[0097] The term, “cancer” refers to any cancer caused by the proliferation of malignant neoplastic cells, such as tumors, neoplasms, carcinomas, sarcomas, leukemias, and lymphomas. Certain cancer types can be characterized by a low white blood cell count, e.g., leukemia. Certain cancer types can be characterized by a low level of complement activity.
[0098] The term, “complement-dependent cytotoxicity” (CDC) refers to a complement system pathway. An example of an activation of this pathway includes activation by IgG and IgM antibodies when they are bound to surface antigens on target cells.
[0099] The term, “effective amount” means an amount that is sufficient, when administered to a population suffering from or susceptible to a disease, disorder, and / or condition in accordance with a therapeutic dosing regimen, to treat the disease, disorder, and / or condition. In some embodiments, a therapeutically effective amount is one that reduces the incidence and / or severity of, and / or delays onset of, one or more symptoms of the disease, disorder, and / or condition. Those of ordinary skill in the art will appreciate that the term “effective amount” does not in fact require successful treatment be achieved in a particular individual. Rather, an effective amount may be that amount that provides a particular desired pharmacological response in a significant number of subjects when administered to patients in need of such treatment. It is specifically understood that particular subjects may, in fact, be “refractory” to an “effective amount.” To give but one example, a refractory subject may have a low bioavailability such that clinical efficacy is not obtainable. In some embodiments, reference to an effective amount may be a reference to an amount as measured in one or more specific tissues (e.g., a tissue affected by the disease, disorder or condition) or fluids (e.g., blood, saliva, serum, sweat, tears, urine). Those of ordinary skill in the art will appreciate that, in some embodiments, an effective amount may be formulated and / or administered in a single dose. In some embodiments, an effective amount may be formulated and / or administered in a plurality of doses, for example, as part of a dosing regimen.
[0100] The term, “graft-versus-host disease”, refers to an immune-driven condition wherein rejection is a consequence of organ or tissue transplantation caused by the transplant recipient's (host's) immunePATENT
[0101] ATTORNEY DOCKET NO.: 51523-007WO2
[0102] response to the transplanted organ / tissue which can damage or destroy it (see also, e.g., “immune-driven condition” and “rejection” definitions). Ordinarily, the immune response protects the body from potentially harmful substances (antigens) such as microorganisms, toxins, and cancer cells. The immune system distinguishes “self” from “foreign” by reacting to proteins on the surfaces of cells. It reacts against substances it recognizes as foreign (antigens). The presence of foreign blood or tissue in the body triggers an immune response that can result in blood transfusion reactions and transplant rejection when antibodies are formed against foreign antigens on the transplanted or transfused material.
[0103] The term, “immune-driven condition” refers to a condition, disease, or disorder in which the subject's immune system is not functioning in normal capacity. This includes subjects that are immunocompromised, meaning an immune system that is functioning below normal levels. Those subjects who can be considered to be immunocompromised include, but are not limited to, subjects with AIDS (or HIV positive), subjects with severe combined immune deficiency (SCID), diabetics, and those who are receiving chemotherapy for cancer. Immunocompromised subjects also include subjects with most forms of cancer (other than skin cancer), sickle cell anemia, cystic fibrosis, those who do not have a spleen, pregnant subjects, subjects with end stage kidney disease (dialysis), and those who have been taking corticosteroids on a frequent basis by pill or injection within the last year. Subjects with severe liver, lung, or heart disease also can be immunocompromised. Immune-driven conditions also include oestrogen-related conditions. Subjects with immune-driven conditions also include subjects with immune systems that perform undesired immune response activity. For example, although immune recognition of foreign proteins is essential to avoid and eliminate infection, under some conditions this immune response can be adverse. Such conditions include, but are not limited to, subjects with allergies, rejection (e.g., rejection of organ post-transplant), or those with autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis, or insulin dependent diabetes mellitus. This can also include subjects with inflammatory diseases and disorders, in which an abnormal or otherwise deregulated inflammatory response contributes to the etiology or severity of disease. Examples include autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, Celiac disease, and diabetes, infectious diseases such as tuberculosis and various forms of meningitis and encephalitis, including West Nile Virus encephalitis as well as ischemia reperfusion diseases such as myocardial infarction and transplant reperfusion injury. Additionally, this includes when there is an increase in inflammation observed after surgery, injury, or other tissue trauma has deleterious effects on a patient's recovery.
[0104] The terms, “immunosuppressive”, “immunosuppression”, and “suppress immune function” are used interchangeably herein and refer to a decrease in the immune response. This includes any condition in which there is a deficiency in the production of humoral and / or cell-mediated immunity.
[0105] The term, “immunoenhancement” and “enhance immune function” are used interchangeably herein and refer to an increase in the immune response, which means there is an increase in the organism’s capacity to respond to foreign or disease-specific antigens (e.g., cancer antigens) i.e. , those cells primed to attach such antigens are increased in number, activity, and ability to detect and destroy those antigens. Strength of immune response can be measured by standard tests including: direct measurement of peripheral blood lymphocytes by means known to the art; natural killer cell cytotoxicity assays (see, e.g., Provinciali M. et al (1992, J. Immunol. Meth. 155: 19-24), cell proliferation assays (see,PATENT
[0106] ATTORNEY DOCKET NO.: 51523-007WO2
[0107] e.g., Vollenweider, I. And Groseurth, P. J. (1992, J. Immunol. Meth. 149: 133-135), immunoassays of immune cells and subsets (see, e.g., Loeffler, D. A., et al. (1992, Cytom. 13: 169-174); Rivoltini, L., et al. (1992, Can. Immunol. Immunother. 34: 241-251); or skin tests for cell-mediated immunity (see, e.g., Chang, A. E. et al. (1993, Cancer Res. 53: 1043-1050). Any statistically significant increase in strength of immune response as measured by the foregoing tests is considered “immunoenhancement” as used herein. Enhanced immune response can also indicated by physical manifestations such as fever and inflammation, as well as healing of systemic and local infections, and reduction of symptoms in disease, i.e., decrease in tumor size, alleviation of symptoms of a disease or condition including, but not restricted to, leprosy, tuberculosis, malaria, naphthous ulcers, herpetic and papillomatous warts, gingivitis, artherosclerosis, the concomitants of AIDS such as Kaposi's sarcoma, bronchial infections, and the like. Such physical manifestations also define “immunoenhancement” as used herein.
[0108] The term, “pregnancy health” refers to the condition of the pregnancy of a pregnant subject. The methods of the invention can be used to evaluate pregnancy health based upon ITIH4 activity of a pregnant subject. Good pregnancy health refers to a pregnancy in which the fetus is considered in a healthy condition based upon ITIH4 activity. Bad pregnancy health refers to a pregnancy in which the fetus is considered in poor health based upon ITIH4 activity. A bad pregnancy health can lead to a rejection of the fetus by the body of the pregnant subject resulting in loss of pregnancy.
[0109] The term, “rejection” refers to an immune-driven condition in which the immune system recognizes a foreign substance (e.g., cell, tissue, organ, therapeutic agent) and attempts to destroy the foreign substance just as the immune system would attempt to destroy infectious microorganisms such as bacteria and viruses. For example, rejection of transplanted organs and tissues can often result in damage to and / or rejection of the transplant. Tissue rejection, also called graft-versus-host disease, is a consequence of organ or tissue transplantation caused by the transplant recipient's (host's) immune response to the transplanted organ / tissue which can damage or destroy it. No two people (except identical twins) have identical tissue antigens. Therefore, in the absence of an immunosuppressive agent, transplantation would almost always cause an immune response against the foreign tissue (rejection), which would result in destruction of the transplant.
[0110] As used here, the term “PAD3 selective inhibitor” refers to an active compound with greater inhibition activity of PAD3 compared to the inhibition activity of PAD1 , PAD2, and PAD4. The PAD3 inhibition IC50 (kinact / Ki(mim1M’1)) is at least 20% less (e.g., more potent) than PAD1 , PAD2, and PAD4 inhibition IC50 (kinact / Ki(mim1M’1)).
[0111] The term “pharmaceutically acceptable salt,” as use herein, represents those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66:1-19, 1977 and in Pharmaceutical Salts: Properties, Selection, and Use, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. The salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately by reacting the free base group with a suitable organic acid. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,PATENT
[0112] ATTORNEY DOCKET NO.: 51523-007WO2
[0113] cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.
[0114] As used herein, the term “pharmaceutical composition” refers to an active compound, or pharmaceutically acceptable salt thereof, formulated together with one or more pharmaceutically acceptable carriers. In some embodiments, active compound or salt is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, pharmaceutical compositions may be specially formulated for parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation. In other embodiments, pharmaceutical compositions include those formulated for oral administration (“oral dosage forms”). Oral dosage forms can be, for example, in the form of tablets, capsules, a liquid solution or suspension, a powder, or liquid or solid crystals, which contain the active ingredient(s) in a mixture with non-toxic pharmaceutically acceptable excipients. These excipients may be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, microcrystalline cellulose, starches including potato starch, calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate, or sodium phosphate); granulating and disintegrating agents (e.g., cellulose derivatives including microcrystalline cellulose, starches including potato starch, croscarmellose sodium, alginates, or alginic acid); binding agents (e.g., sucrose, glucose, sorbitol, acacia, alginic acid, sodium alginate, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, carboxymethylcellulose sodium, methylcellulose, hydroxypropyl methylcellulose, ethylcellulose, polyvinylpyrrolidone, or polyethylene glycol); and lubricating agents, glidants, and antiadhesives (e.g., magnesium stearate, zinc stearate, stearic acid, silicas, hydrogenated vegetable oils, or talc). In other embodiments, pharmaceutical compositions include those formulated for topical administration (e.g., as a cream, gel, lotion, or ointment). Other pharmaceutically acceptable excipients can be colorants, flavoring agents, plasticizers, humectants, buffering agents, and the like. Compositions for oral administration may also be presented as chewable tablets, as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent (e.g., potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin), or as soft gelatin capsules where the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil. Powders, granulates, and pellets may be prepared using the ingredients mentioned above under tablets and capsules in a conventional manner using, e.g., a mixer, a fluid bed apparatus or a spray drying equipment.
[0115] The term “subject,” as used herein, represents a human or non-human animal (e.g., a mammal).PATENT
[0116] ATTORNEY DOCKET NO.: 51523-007WO2
[0117] The term, “therapeutic agent” refers to a chemical compound, such as a small molecule, steroid, nucleic acid molecule, or other biological agent, such as a protein, lipid, or enzyme intended to result in the treatment of a subject. For example, in the present invention, a therapeutic agent may include a therapy intended to modulate an immune response.
[0118] The term, “treatment” (also “treat” or “treating”), in its broadest sense, refers to any administration of a substance that partially or completely alleviates, ameliorates, relives, inhibits, delays onset of, reduces severity of, and / or reduces incidence of one or more symptoms, features, and / or causes of a particular disease, disorder, and / or condition. In some embodiments, such treatment may be administered to a subject who does not exhibit signs of the relevant disease, disorder and / or condition and / or of a subject who exhibits only early signs of the disease, disorder, and / or condition. Alternatively, or additionally, in some embodiments, treatment may be administered to a subject who exhibits one or more established signs of the relevant disease, disorder and / or condition. In some embodiments, treatment may be of a subject who has been diagnosed as suffering from the relevant disease, disorder, and / or condition. In some embodiments, treatment may be of a subject known to have one or more susceptibility factors that are statistically correlated with increased risk of development of the relevant disease, disorder, and / or condition.
[0119] Other features and advantages of the invention will be apparent from the following Detailed Description, the Drawings, and the claims.
[0120] Brief Description of the Drawings
[0121] Figs. 1A-1C shows the results of analyzing the influence of the PAD3 inhibitor CAY10727 on ITIH4 activity. Fig. 1 A shows a western blot gel stained with anti-His directly conjugated antibody of samples containing ITIH4-His and other agents of interest for comparison in contact with serum from healthy individuals. Fig. 1 B shows the composition in each lane of the gel in A, in which CAY10727 in in lane I6. Fig. 1C shows a western blot gel demonstrating PAD3 inhibition using various doses of C1-amidine or CAY10727, which activates ITIH4-His in non-pregnant plasma samples, revealing higher potency of CAY10727 as a PAD3 inhibitor.
[0122] Fig.2 is a gel showing western blot for detection of PAD3 protein in serum with rabbit anti PAD3 monoclonal antibody. The lanes show PAD3 control protein, normal serum (nonpregnant subject), and pregnant serum (third term pregnancy).
[0123] Figs.3A-3C are bar graphs displaying the effects of PAD inhibitor C1 -amidine on complement pathway activity in non-pregnancy serum samples. Fig.3A is the classical pathway. Fig.3B is the MP pathway. Fig.3C is the AP pathway.
[0124] Detailed Description of the Invention
[0125] The interaction between endogenous proteases and protease inhibitors is crucial for the precise regulation of immune responses and the maintenance of self-tolerance. This balance ensures that the immune system can effectively combat pathogens while avoiding damage to host tissues and preventing autoimmunity.
[0126] The immune system produces desired immune responses in the body of an organism when it protects the organism from harm through identifying and destroying foreign substances. The complementPATENT
[0127] ATTORNEY DOCKET NO.: 51523-007WO2
[0128] system is considered an integral part of the innate immune system and is an example of such a system. Complement is considered to be activated by proteases and regulated by protease inhibitors in either the lectin pathway (LP), classical pathway (CP), or the alternative pathway (AP). Human plasma contains factors which determine the activity of the complement system to produce a desired immune response. For example, in the plasma of pregnant humans, activity is regulated in order to avoid an immune response that would harm the fetus. Alternatively, complement system activity (e.g., complementdependent cytotoxicity (CDC)) could be promoted to destroy harmful cells (e.g., bacterial or viral infected cells). In immune-driven conditions, undesired immune responses can arise, which is when the immune system (e.g., complement system) does not modulate its activity appropriately to protect the organism from harm. For example, some types of cancers may produce inhibitors in the organism that decrease the complement system activity in order to suppress the immune system and allow the cancerous cells to avoid CDC. This results in an undesired immune tolerance of cancer cells. Alternatively, an immune-driven condition can result in an undesired immunoenhancement, in which immune tolerance may be lost, as is seen in autoimmune disease and graft-versus-host disease. In both conditions it can be hypothesized that the presence or absence of specific complement regulation factors in the human plasma to be the cause.
[0129] The ITIH4 protein is hypothesized to be a significant contributor to immune-driven conditions. ITIH4 activity is regulated in part by citrullination, the chemical conversion of arginine (Arg), specifically the guanidinium functionality, to citrulline. In some instances, a peptidyl-arginine deiminase (PAD3)-mediated citrullination can be involved in the deactivation of ITIH4.
[0130] PAD3
[0131] Peptidyl-arginine deiminase 3 (PAD3) has previously been characterized as a modulator of cell growth via apoptosis inducing factor-mediated apoptosis. A PAD3-mediated citrullination of AIF was identified as crucial for translocation to the nucleus to induce cell death (see, e.g., N. D.; Ferretti, et al. Dev. Biol. 2011 , 355 (2), 205-14). PAD3 activity has also been associated with neurodegenerative response to spinal cord injury. Additionally, PAD3-mediated citrullination of proteins has been observed during lactation (see, e.g., Cherrington, B. D. et al. PLoS One 2016, 11 (1), e0147503).
[0132] Notably, PAD3-mediated citrullination was found to play an integral role in ITIH4 modulation by deactivating ITIH4, which allows for enhanced immune responses. For example, a correlation has been observed between an increased amount of citrullination of ITIH4 over time and advancing rheumatoid arthritis in a subject (see, e.g., US 11 ,774,447). As PAD3 has been found to be crucial to the citrullination deactivation pathway, inhibiting PAD3 has proved to be an effective strategy for activating ITIH4 via reducing PAD3-mediated citrullination in cells (Fig. 1). Also the absence of PAD3 in serum from term 3 pregnant woman, with activated ITIH4, demonstrates the necessity of this factor for inhibition of activity of ITIH4, demonstrating a value of the use of PAD3 as a protein therapeutic for replacement therapy in immunosuppressive conditions such as cancer.
[0133] The present invention is directed to PAD3 activity modulators to regulate immune function (e.g., immunoenhancement or immunosuppression) in subjects with immune-driven conditions.PATENT
[0134] ATTORNEY DOCKET NO.: 51523-007WO2
[0135] Small Molecule PAD3 Inhibitors
[0136] A PAD3 inhibitor of the present invention may bind reversibly or irreversibly.
[0137] A PAD3 inhibitor of the present invention may be a compound of formula (I):
[0138]
[0139] or a pharmaceutically acceptable salt thereof, wherein,
[0140] n is 0, 1 , 2, 3, or 4;
[0141] X is Cl or F;
[0142]
[0143] Y is H, C1-C3 alkyl, or R2, where = is either a single bond or a double bond;
[0144] substitut
[0145]
[0146]
[0147] two R1together with the atoms to which they are bound form an optionally substituted 5- to 6-memeberred C2-C5 heterocyclyl or optionally substituted 5- to 6-membered C2- C5 heteroaryl;
[0148] R2is H, C1-C3 alkyl, O, or Ce aryl;
[0149] R3is H, C1-C3 alkyl, Ce aryl,
[0150]
[0151] R2and R3together with the atoms to which they are attached combine to form a Ce aryl or a 6- to 10-membered C5-C7 heteroaryl;
[0152]
[0153] each R5is independently -O-(Ci-C3 alkyl), -CO2H, or halogen; or
[0154] two R5together with the atoms to which they are attached form an optionally substituted 5- to 6-membered heterocyclyl;
[0155] L is bond or -C(O)NH-; and
[0156] each optionally substituted group is optionally substituted with 1 , 2, 3, or 4 substituents independently selected from a group consisting of: C1-C3 alkyl, -O-(Ci-C3 alkyl), halogen, and =0.PATENT
[0157] ATTORNEY DOCKET NO.: 51523-007WO2
[0158] In some embodiments, the PAD3 inhibitor is of formula (la):
[0159]
[0160] or a pharmaceutically acceptable salt thereof.
[0161] In specific embodiments, a PAD3 inhibitor of the present invention may be a compound of formula (II):
[0162]
[0163] or a pharmaceutically acceptable salt thereof, wherein,
[0164] n is 0, 1 , 2, 3, or 4;
[0165] each Z1, Z2, and Z3are independently CR1, NR1, O,
[0166]
[0167] , each R1is independently H, C1-C3 alkyl, =0, halogen, or two R1together with the atoms to which they are bound form an optionally substituted 5- to 6-memeberred C2-C5 heterocyclyl or optionally substituted 5- to 6-membered C2-C5 heteroaryl;
[0168] R2is H, C1-C3 alkyl, or Ce aryl;
[0169]
[0170] R2and R3together with the atoms to which they are attached combine to form a Ce aryl; each R5is independently -O-(Ci-C3 alkyl) or halogen;
[0171] L is bond or -C(O)NH-; and
[0172] each optionally substituted group is optionally substituted with 1 , 2, 3, or 4 substituents independently selected from a group consisting of: C1-C3 alkyl, -O-(Ci-C3 alkyl), halogen, and =0.
[0173]
[0174] PATENT
[0175] ATTORNEY DOCKET NO.: 51523-007WO2
[0176] In some embodiments, -
[0177]
[0178] A PAD3 inhibitor in the present invention may be a compound in Table 1 , or a pharmaceutically acceptable salt thereof (e.g., HCI salt). In some particular embodiments, the PAD3 inhibitor is Compound 1 , Compound 30, or a pharmaceutically acceptable salt thereof (e.g., HCI salt). Compounds 1 through 20 can be prepared using the procedures described in, Ellman, J. A. et al. J. Am. Chem. Soc. 2015, 137(10), 3616-3621 . Compounds 21 through 28 can be prepared using the procedures described in, Ellman, J. A. et al. ACS Med. Chem. Lett. 2016, 7, 847-851 . Compounds of the present inventions may be prepared by known synthetic methods, such as those described by Ellman et al. A PAD3 selective inhibitor is selective for PAD3 over PAD1 , PAD2, and PAD4, where PAD3 inhibition IC50 (kinact / Ki(min-1M'1)) is at least 20% less than PAD1 , PAD2, and PAD4 inhibition IC5o(kinact / Ki(mim1M'1)). Preferably, a PAD3 selective inhibitor is at least 4-fold more selective for PAD3 inhibition over PAD1 , PAD2, and PAD4. More preferably, a PAD3 selective inhibitor is at least 10-fold more selective for PAD3 over PAD1 , PAD2, and PAD4 (e.g., Compound 1 and Compound 2). The PAD3 inhibition compared to PAD1 , PAD2, and PAD4 inhibition for the Compounds 1 through 20 is described in, Ellman, J. A. et al. J. Am. Chem. Soc. 2015, 137(10), 3616-3621 . The PAD3 inhibition compared to PAD1 , PAD2, and PAD4 inhibition for the Compounds 21 through 28 in Table 1 is described in, Ellman, J. A. et al. ACS Med. Chem. Lett. 2016, 7, 847-851 .PATENT
[0179] ATTORNEY DOCKET NO.: 51523-007WO2
[0180]
[0181] PATENT
[0182] ATTORNEY DOCKET NO.: 51523-007WO2
[0183]
[0184] PATENT
[0185] ATTORNEY DOCKET NO.: 51523-007WO2
[0186]
[0187] PATENT
[0188] ATTORNEY DOCKET NO.: 51523-007WO2
[0189]
[0190] and pharmaceutically acceptable salts thereof.
[0191] PAD3 therapeutics
[0192] A therapeutic of the present invention may include a PAD3 protein or derivative thereof, e.g., a fragment or dimer. A PAD3 protein may include an amino acid sequence at least 80% identical to SEQ ID No. 1 (see, e.g., Lott, S. J. et al. Acta Cryst. 2021 , F77, 334-340).
[0193] SEQ ID No. 1:
[0194] MSYYHHHHHHLESTSLYKKAGFMSLQRIVRVSLEHPTSAVCVAGVETLVDIYGSVPEGTEMFEVYGTPG VDIYISPNMERGRERADTRRWRFDATLEIIVVMNSPSNDLNDSHVQISYHSSHEPLPLAYAVLYLTCVDISL DCDLNCEGRQDRNFVDKRQWVWGPSGYGGILLVNCDRDDPSCDVQDNCDQHVHCLQDLEDMSVMVL RTQGPAALFDDHKLVLHTSSYDAKRAQVFHICGPEDVCEAYRHVLGQDKVSYEVPRLHGDEERFFVEGL SFPDAGFTGLISFHVTLLDDSNEDFSASPIFTDTVVFRVAPWIMTPSTLPPLEVYVCRVRNNTCFVDAVAE LARKAGCKLTICPQAENRNDRWIQDEMELGYVQAPHKTLPVVFDSPRNGELQDFPYKRILGPDFGYVTR EPRDRSVSGLDSFGNLEVSPPVVANGKEYPLGRILIGGNLPGSSGRRVTQVVRDFLHAQKVQPPVELFV DWLAVGHVDEFLSFVPAPDGKGFRMLLASPGACFKLFQEKQKCGHGRALLFQGVVDDEQVKTISINQVL SNKDLINYNKFVQSCIDWNREVLKRELGLAECDIIDIPQLFKTERKKATAFFPDLVNMLVLGKHLGIPKPFG PIINGCCCLEEKVRSLLEPLGLHCTFIDDFTPYHMLHGEVHCGTNVCRKPFSFKWWNMVP
[0195] Ant-PAD3 Antibodies
[0196] In some embodiments, the antibody of the present invention is a purified antibody such as a purified autoantibody that can inhibit PAD3 by targeting a region of the catalytic domain (e.g., a portion of residues from residues 293-664 as numbered on human PAD3) or blocking one or more residues involved in PAD3 dimerization (e.g., a dimerization site, such as any one or more residues of Arg8, Tyr30, Phe279, Pro283, Phe497, Tyr540, Phe543, Asp549, and / or Trp550 as numbered on human PAD3). In some embodiments, the antibody of the present invention is a purified antibody such as a purified autoantibody that can enhance PAD3 activity (e.g., enhancing citrullination activity of PAD3) via allosteric regulation. The antibody of the present invention may bind a linear epitope or a conformational epitope of PAD3. The autoantibody may be one previously identified, e.g., see US8975033B2 and Martinez-Prat, L. et al. (Expert Rev. Clin. Immunolh , 1073-1087, 2019), the disclosure of each of which is incorporated by reference herein.PATENT
[0197] ATTORNEY DOCKET NO.: 51523-007WO2
[0198] As an example, a candidate anti-PAD3 antibody may be identified for use in the methods of the invention by affinity purifying an anti-PAD3 antibody from a biological sample that comprises one or more autoantibodies (e.g., a plasma sample obtained from a subject) such that the candidate anti-PAD3 antibody is at least 80%, at least 85%, at least 90%, or at least 95% purified in solution, and then determining the candidate anti-PAD3 antibody sequence via a liquid chromatography-mass spectrometry approach. As another example, a candidate anti-PAD3 antibody may be identified by obtaining one or more memory B-cells or plasma cells from a subject that produces one or more anti-PAD3 autoantibodies, cultivating the one or more memory B-cells or plasma cells via in vitro cell culture methods such that the memory B-cells or plasma cells are cultured as single clones, and then evaluating the binding capacity (e.g., detecting binding or determining binding affinity) of a cell culture supernatant that contains a candidate anti-PAD3 antibody to a PAD3 protein or fragment thereof. If a cell culture supernatant is identified as binding to PAD3 or a fragment thereof, the memory B-cell or plasma cell clone may be processed via standard antibody cloning methods to clone, express, and purify a candidate anti-PAD3 antibody. Exemplary methods of antibody purification and antibody isolation from biological samples are routine in the art and are described elsewhere such as, e.g., in Roque et al. (J Chromatogr. A. 1160(1 -2) :44-55, 2007); Corti and Lanzavecchia. (Microbiol. Spectr. 2(5), 2014); Waller-Pulido et al. (Int. Immunopharmacol. 120:110376, 2023); WO 2009 / 138484; and WO 2014 / 145065, each of which are hereby incorporated by reference.
[0199] An antibody or antibody fragment that binds PAD3 or a fragment thereof (e.g., an inhibitory or activating antibody or antibody fragment thereof) can be characterized by a variety of established methods and selected for use in a method of the invention based on, e.g., its affinity or activity. The affinity can be represented quantitatively by various metrics, including the equilibrium constant (KD) of the antibody-PAD3 complex dissociation. The equilibrium constant, KD, which describes the interaction of PAD3 with an antibody or antigen-binding fragment thereof of the invention is the chemical equilibrium constant for the dissociation reaction of a PAD3-antibody complex into solvent-separated PAD3 and antibody molecules that do not interact with one another. The equilibrium constant KD of any antibody or antigen-binding fragment thereof may be determined via an ELISA, isothermal titration, calorimetry, microscale thermophoresis, surface plasmon resonance (SPR), or bio-layer interferometry (BLI), In addition to the thermodynamic parameters of an anti-PAD3 antibody interaction, it is also possible to quantitatively characterize the kinetic association and dissociation of an antibody or antibody fragment of the invention with PAD3. This can be done by monitoring the rate of antibody-antigen complex formation according to established procedures. For example, the rate of antibody-PAD3 complex formation (kon) or dissociation (kotf) may be evaluated via SPR or BLI.
[0200] An antibody or antigen-binding fragment thereof of the invention is one that specifically bind to PAD3 with a KD value of less than 100 nM (e.g., 95 nM, 90 nM, 85 nM, 80 nM, 75 nM, 70 nM, 65 nM, 60 nM, 55 nM, 50 nM, 45 nM, 40 nM, 35 nM, 30 nM, 25 nM, 20 nM, 15 nM, 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, or 1 nM). In some embodiments, an antibody of the invention is one that specifically bind to PAD3 with a KD value of less than 1 nM (e.g., 990 pM, 980 pM, 970 pM, 960 pM, 950 pM, 940 pM, 930 pM, 920 pM, 910 pM, 900 pM, 890 pM, 880 pM, 870 pM, 860 pM, 850 pM, 840 pM, 830 pM, 820 pM, 810 pM, 800 pM, 790 pM, 780 pM, 770 pM, 760 pM, 750 pM, 740 pM, 730 pM, 720 pM, 710 pM, 700 pM, 690 pM, 680 pM, 670 pM, 660 pM, 650 pM, 640 pM, 630 pM, 620 pM, 610 pM, 600 pM, 590 pM, 580 pM, 570 pM, 560 pM,PATENT
[0201] ATTORNEY DOCKET NO.: 51523-007WO2
[0202] 550 pM, 540 pM, 530 pM, 520 pM, 510 pM, 500 pM, 490 pM, 480 pM, 470 pM, 460 pM, 450 pM, 440 pM, 430 pM, 420 pM, 410 pM, 400 pM, 390 pM, 380 pM, 370 pM, 360 pM, 350 pM, 340 pM, 330 pM, 320 pM, 310 pM, 300 pM, 290 pM, 280 pM, 270 pM, 260 pM, 250 pM, 240 pM, 230 pM, 220 pM, 210 pM, 200 pM, 190 pM, 180 pM, 170 pM, 160 pM, 150 pM, 140 pM, 130 pM, 120 pM, 110 pM, 100 pM, 90 pM, 80 pM, 70 pM, 60 pM, 50 pM, 40 pM, 30 pM, 20 pM, 10 pM, 5 pM, or 1 pM).
[0203] An antibody or antigen-binding fragment thereof of the invention exhibits high kon and low kotf values upon interaction with PAD3, consistent with high-affinity binding. For example, antibodies of the invention may exhibit kon values in the presence of PAD3 of greater than 104M'1s1(e.g., 1 .0 x 104M'1s1, 1 .5 x 104M-1s1, 2.0 x 104M-1s1, 2.5 x 104M'1S'1, 3.0 x 104M'1S'1, 3.5 x 104M'1S'1, 4.0 x 104M'1S'1, 4.5 x 104M-1s-1, 5.0 x 104M-1s1, 5.5 x 104M'1S'1, 6.0 x 104M'1S'1, 6.5 x 104M'1S'1, 7.0 x 104M'1S'1, 7.5 x 104M'1s1, 8.0 x 104M-1s1, 8.5 x 104M'1S'1, 9.0 x 104M'1S'1, 9.5 x 104M'1S'1, 1 .0 x 105M'1S'1, 1 .5 x 105M'1S'1, 2.0 x 105M-1s1, 2.5 x 105M-1s1, 3.0 x 105M'1S'1, 3.5 x 105M'1S'1, 4.0 x 105M'1S'1, 4.5 x 105M'1S'1, 5.0 x 105M'1S'1, 5.5 x 105M'1S'1, 6.0 x 105M'1S'1, 6.5 x 105M'1S'1, 7.0 x 105M'1S'1, 7.5 x 105M'1S'1, 8.0 x 105M'1S'1, 8.5 x 105M1S'1, 9.0 x 105M'1s1, 9.5 x 105M'1s1, or 1 .0 x 106M'1s1). An antibody of the invention exhibits low kotf values when bound to PAD3, which is indicative of a slow dissociate rate and strong intermolecular contacts. For instance, an antibody of the invention may exhibit kotf values of less than 10'3S'1when complexed to PAD3 (e.g., 1 .0 x 103s1, 9.5 x 104s1, 9.0 x 1 O'4s1, 8.5 x 104s1, 8.0 x 104s1, 7.5 x 10'4S'1, 7.0 x 10'4S'1, 6.5 x 10'4S'1, 6.0 x 104s1, 5.5 x 104s1, 5.0 x 104s1, 4.5 x 104s1, 4.0 x 104S'1, 3.5 x 10'4S'1, 3.0 x 10'4S'1, 2.5 x 104s1, 2.0 x 104s1, 1 .5 x 104s1, 1 .0 x 104s1, 9.5 x 105s1, 9.0 x 105S'1, 8.5 x 105S'1, 8.0 x 105s1, 7.5 x 105s1, 7.0 x 105s1, 6.5 x 105s1, 6.0 x 105s1, 5.5 x 105s1, 5.0 x 10'5S'1, 4.5 x 10'5S'1, 4.0 x 105s4, 3.5 x 105s1, 3.0 x 105s4, 2.5 x 105s1, 2.0 x 105s1, 1.5 x 105S'1, or 1 .0 x 10'5S'1).
[0204] In some embodiments, a PAD3 inhibitor or activator is an antigen-binding fragment of an antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab’, Fab’-SH, F(ab’)2; diabodies, triabodies, tetrabodies, cross-Fab fragments, linear antibodies, single chain antibody molecules (e.g., scFv), multispecific antibodies formed from antibody fragments and single domain antibodies. Various antibody fragments are detailed elsewhere, e.g., in Hudson et al. (A / atMerf9:129-134, 2003). Additionally, scFv fragments are described elsewhere, e.g., in Pluckthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); WO 93 / 16185; and U.S. Patent Nos. 5,571 ,894 and 5,587,458. Fab and F(ab’)2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life are discussed in U.S. Patent No. 5,869,046. Diabodies are antibody fragments with two antigen-binding domains that may be bivalent or bispecific, see, for example, US 202030382996; WO 1993 / 01161 ;
[0205] Hudson et al. (Nat Med. 9:129-134, 2003). Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see e.g., U.S. Patent No. 6,248,516 B1). In addition, antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain, namely being able to assemble together with a VH domain to a functional antigen binding site and thereby providing the antigen binding property of full-length antibodies. Antibody fragments can be made by various techniques, including but not limited toPATENT
[0206] ATTORNEY DOCKET NO.: 51523-007WO2
[0207] proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g., E. colior phage), as described herein.
[0208] Antibody fragments may be produced from a full-length antibody (e.g., a full-length IgG antibody) via proteolytic digestion. Fab fragments containing each of the heavy- and light-chain variable domains and the constant domain of the light chain (CL) and the first constant domain (CH1) of the heavy chain may be produced via papain digestion of intact antibodies, thereby producing two identical antigenbinding fragments. Fab’ fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab’-SH are Fab’ fragments wherein the cysteine residue(s) of the constant domains bear a free thiol group. Pepsin treatment yields an F(ab’)2 fragment that has two antigen-combining sites (two Fab fragments) and a part of the Fc region.
[0209] Another exemplary antigen-binding fragment is a single-chain variable fragment (scFv), which is a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of an antibody, connected with a short linker peptide of ten to about 25 amino acids. A linker is typically rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N-terminus of the VH with the C-terminus of the VL, or vice versa. An scFv retains the specificity of the original antibody, despite removal of the constant regions and the introduction of the linker.
[0210] An antibody or antigen-binding fragment thereof of the present invention, e.g., an antibody purified from a biological sample that contains autoantibodies as described herein, may be used to inhibit PAD3 activity (e.g., inhibit the rate or magnitude of citrullination activity by PAD3) as compared to PAD3 without the addition of the antibody or antigen-binding fragment thereof. An antibody or antigen-binding fragment thereof that inhibits PAD3 activity may be used as an immunosuppressant according to the methods described herein. In some embodiments, an antibody or antigen-binding fragment inhibits PAD3 activity upon binding such that the PAD3 activity is reduced by 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2 times, 3 times, 4 times, 5 times, 10 times, or 20 times as compared to PAD3 activity in the absence of the antibody or antigen-binding fragment thereof. In some embodiments, an antibody or antigen-binding fragment inhibits PAD3 activity upon binding such that PAD3 activity is reduced by about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or greater than 80% (e.g., about 85%, about 90%, or about 95%) as compared to PAD3 activity in the absence of the antibody or antigen-binding fragment thereof.
[0211] Conversely, an antibody or antigen-binding fragment thereof of the present invention, e.g., an antibody purified from a biological sample that contains autoantibodies as described herein, may be used to enhance PAD3 activity (e.g., enhance the rate or magnitude of citrullination activity by PAD3) as compared to PAD3 without the addition of the antibody or antigen-binding fragment thereof. An antibody or antigen-binding fragment thereof that enhances PAD3 may be used in the treatment of a cancer susceptible to immunotherapy (e.g., as described herein). In some embodiments, an antibody or antigenbinding fragment enhances PAD3 activity upon binding such that the PAD3 activity is 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 1.9 times, 2 times, 3 times, 4 times, 5 times, 10 times, or 20 times as compared to PAD3 activity in the absence of the antibody or antigen-binding fragment thereof. In some embodiments, an antibody or antigen-binding fragment enhances PAD3 activity upon binding such that PAD3 activity increases by about 5%, about 10%, about 20%, about 30%,PATENT
[0212] ATTORNEY DOCKET NO.: 51523-007WO2
[0213] about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 100%, or greater than 100% (e.g., by about 150%, about 175%, about 200%, or about 500%) as compared to PAD3 activity in the absence of the antibody or antigen-binding fragment thereof.
[0214] Gene Therapy
[0215] In one aspect, a PAD3 protein or fragment thereof (e.g., a PAD3 protein fragment that includes a domain of PAD3 such as the catalytic domain) or a PAD3 inhibitor of the present invention will be administered as a gene therapy (e.g., via a polynucleotide encoding PAD3 or a fragment thereof or a PAD3 inhibitor (e.g., an inhibitory anti-PAD3 antibody or antigen-binding fragment thereof)).
[0216] In some embodiments, a polynucleotide encoding a PAD3 protein or fragment thereof or PAD3 inhibitor is delivered to a cell of a subject via a viral genome. Viral genomes provide a rich source of vectors that can be used for the efficient delivery of a gene of interest (e.g., a gene encoding PAD3 or a fragment thereof or a gene encoding a PAD3 inhibitor such as an inhibitory anti-PAD3 antibody or antigen-binding fragment thereof) into the genome of a target cell in a host (e.g., a human subject). Viral genomes are particularly useful vectors for gene delivery because the polynucleotides contained within such genomes are typically incorporated into the genome of a target cell by generalized or specialized transduction. These processes occur as part of the natural viral replication cycle, and do not require added proteins or reagents in order to induce gene integration. Examples of viral vectors that may be used for delivery of a polynucleotide encoding a PAD3 protein or fragment thereof or a PAD3 inhibitor (e.g., an inhibitory anti-PAD3 antibody or antigen-binding fragment thereof) are adeno-associated virus (AAV), retrovirus, adenovirus (e.g., Ad5, Ad26, Ad34, Ad35, and Ad48), parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g. measles and Sendai), positive strand RNA viruses, such as picornavirus and alphavirus, and double stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, modified vaccinia Ankara (MVA), fowlpox and canarypox). Other viruses that may be used for delivery of a polynucleotide encoding a PAD3 protein or fragment thereof or a include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example. Examples of retroviruses include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D-type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields, et al., Eds., Lippincott-Raven Publishers, Philadelphia, 1996). Other examples include murine leukemia viruses, murine sarcoma viruses, mouse mammary tumor virus, bovine leukemia virus, feline leukemia virus, feline sarcoma virus, avian leukemia virus, human T-cell leukemia virus, baboon endogenous virus, Gibbon ape leukemia virus, Mason Pfizer monkey virus, simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virus and lentiviruses. Other examples of vectors are described, for example, in U.S. Patent No. 5,801 ,030, the disclosure of which is incorporated herein by reference as it pertains to viral vectors for use in gene therapy.
[0217] In some embodiments, a polynucleotide encoding a PAD3 protein or fragment thereof or a PAD3 inhibitor (e.g., an inhibitory anti-PAD3 antibody or antigen-binding fragment thereof) is incorporated into recombinant AAV (rAAV) vector to facilitate introduction into a cell (e.g., a cell of a human subject). rAAVPATENT
[0218] ATTORNEY DOCKET NO.: 51523-007WO2
[0219] vectors for delivery of a PAD3 protein or fragment thereof or a PAD3 inhibitor (e.g., an inhibitory anti-PAD3 antibody or an antigen-binding fragment thereof) to a cell of a host include recombinant nucleic acid constructs that contain (1) a polynucleotide sequence that encodes a PAD3 protein or fragment thereof or a PAD3 inhibitor (e.g., an inhibitory anti-PAD3 antibody or antigen-binding fragment thereof) for protein production and (2) one or more nucleic acids that facilitate expression of protein. The viral nucleic acids may include those cis-acting elements of rAAV for replication and packaging (e.g., functional inverted terminal repeats (ITRs)) of the DNA into a virion. Such rAAV vectors may also contain marker or reporter genes. Useful rAAV vectors include those having one or more of the naturally-occurring AAV genes deleted in whole or in part, but retain functional flanking ITR sequences. The AAV ITRs may be of any serotype (e.g., derived from serotype 2) suitable for a particular application. Exemplary rAAV vectors and methods of use are described, for example, in Tai et al. (J. Biomed. Sci. 7:279-291 , 2000), Monahan and Samulski (Gene Delivery. 7:24-30, 2000), and US20210198428A1 , the disclosures of each of which are incorporated herein by reference as they pertain to AAV vectors for gene delivery.
[0220] The nucleic acids and vectors described herein can be incorporated into a rAAV virion in order to facilitate introduction of the nucleic acid or vector into a cell. The capsid proteins of AAV compose the exterior, non-nucleic acid portion of the virion and are encoded by the AAV cap gene. The cap gene encodes three viral coat proteins, VP1 , VP2 and VP3, which are required for virion assembly. The construction of rAAV virions has been described, for example, in U.S. Patent Nos. 5,173,414; 5,139,941 ; 5,863,541 ; 5,869,305; 6,057,152; and 6,376,237; as well as in Rabinowitz et al. (J. Virol. 76:791-801 , 2002) and Bowles et al. (J. Virol. 77:423-432, 2003), the disclosures of each of which are incorporated herein by reference as they pertain to AAV vectors for gene delivery.
[0221] rAAV virions useful for delivering a PAD3 protein or fragment thereof or a PAD3 inhibitor (e.g., an inhibitory anti-PAD3 antibody or antigen-binding fragment thereof) to a target cell (e.g., a cell of a subject) include those derived from a variety of AAV serotypes including AAV 1 , 2, 3, 4, 5, 6, 7, 8, and 9, among others. Construction and use of AAV vectors and AAV proteins of different serotypes are described, for example, in Chao et al., Mol. Ther. 2:619-623, 2000), Davidson et al. (Proc. Natl. Acad. Sci. USA 97:3428-3432, 2000), Xiao et al. (J. Virol. 72: 2224-2232, 1998), Halbert et al. (J. Virol. 74: 1524-1532, 2000); Halbert et al. (J. Virol. 75: 6615-6624, 2001), and Auricchio et al. (Hum. Molec. Genet. 10: 3075-3081 , 2001), the disclosures of each of which are incorporated herein by reference as they pertain to AAV vectors for gene delivery.
[0222] Also useful for delivering a PAD3 protein or fragment thereof or a PAD3 inhibitor (e.g., an inhibitory anti-PAD3 antibody or antigen-binding fragment thereof) to a target cell are pseudotyped rAAV vectors. Pseudotyped vectors include AAV vectors of a given serotype (e.g., AAV2) pseudotyped with a capsid protein derived from a serotype other than the given serotype (e.g., AAV1 , AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, or AAV9, among others). For example, a representative pseudotyped vector is an AAV2 vector encoding a therapeutic protein pseudotyped with a capsid protein derived from AAV serotype 8 or AAV serotype 9. In some embodiments, the pseudotyped AAV has the ITRs of one AAV serotype (e.g., AAV2) and the VP1 , VP2, and / or VP3 capsid proteins from a different AAV serotype (e.g., AAV1 , AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh , or AAVrh74). Techniques involving the construction and use of pseudotyped rAAV virions are known in the art and are described, for example, in Duan et al. (J. Virol. 75:7662-7671 , 2001); Halbert et al. (J. Virol. 74: 1524-1532, 2000);PATENT
[0223] ATTORNEY DOCKET NO.: 51523-007WO2
[0224] Zolotukhin et al. (Methods. 28: 158-167, 2002); and Auricchio et al. (Hum. Molec. Genet. 10: 3075-3081 , 2001).
[0225] In some embodiments, the AAV comprises a capsid disclosed, e.g., in WO 2017 / 218842, the disclosure of which is incorporated herein by reference. In some embodiments, the AAV comprises a capsid protein disclosed in Lin et al. (Mol Brain. 13:138, 2020), the disclosure of which is incorporated herein by reference. In some embodiments, the AAV comprises an AAV2-retro or an AAV9-retro capsid protein. In some embodiments, the AAV comprises a capsid protein that is conjugated to a ligand or an aptamer.
[0226] AAV virions that have mutations within the virion capsid may be used to infect particular cell types more effectively than non-mutated capsid virions. For example, suitable AAV mutants may have ligand insertion mutations for the facilitation of targeting AAV to specific cell types. The construction and characterization of AAV capsid mutants including insertion mutants, alanine screening mutants, and epitope tag mutants is described in Wu et al. (J. Virol. 74: 8635-45, 2000). Other rAAV virions that can be used in methods of the invention include those capsid hybrids that are generated by molecular breeding of viruses as well as by exon shuffling. See, e.g., Soong et al. (Nat. Genet. 25: 436-439, 2000) and Kolman and Stemmer (Nat. Biotechnol. 19: 423-428, 2001).
[0227] In addition to virus-based delivery modalities, various non-viral techniques can also be used to deliver a polynucleotide that encodes a PAD3 protein or fragment thereof or a PAD3 inhibitor (e.g., an inhibitory anti-PAD3 antibody or antigen-binding fragment thereof) to a subject or cell (e.g., a cell of a human subject such as a cell obtained from a human subject). For example, electroporation can be used to permeabilize mammalian cells (e.g., human cells) by the application of an electrostatic potential to the cell of interest. Mammalian cells, such as human cells, subjected to an external electric field in this manner are subsequently predisposed to the uptake of exogenous nucleic acids. Electroporation of mammalian cells is described in detail, e.g., in Chu et al. (Nucleic Acids Res. 15: 1311 , 1987), the disclosure of which is incorporated herein by reference. A similar technique, Nucleofection™, utilizes an applied electric field in order to stimulate the uptake of exogenous polynucleotides into the nucleus of a eukaryotic cell. Nucleofection™ and protocols useful for performing this technique are described in detail, e.g., in Distler et al. (Exp. Dermatol. 14:315, 2005), as well as in US 2010 / 0317114, the disclosures of each of which are incorporated herein by reference.
[0228] Additional techniques useful for the transfection of a target cell include the squeeze-poration methodology. This technique induces the rapid mechanical deformation of cells in order to stimulate the uptake of exogenous DNA through membranous pores that form in response to the applied stress. This technology is advantageous in that a vector is not required for delivery of nucleic acids into a cell, such as a human target cell. Squeeze-poration is described in detail, e.g., in Sharei et al. (J. Vis. Exp. 81 :e50980, 2013), the disclosure of which is incorporated herein by reference.
[0229] Lipofection represents another technique useful for transfection of a target cell. This method involves the loading of nucleic acids into a liposome, which often presents cationic functional groups, such as quaternary or protonated amines, towards the liposome exterior. This promotes electrostatic interactions between the liposome and a cell due to the anionic nature of the cell membrane, which ultimately leads to uptake of the exogenous nucleic acids, for example, by direct fusion of the liposome with the cell membrane or by endocytosis of the complex. Lipofection is described in detail, for example,PATENT
[0230] ATTORNEY DOCKET NO.: 51523-007WO2
[0231] in US Patent No. 7,442,386, the disclosure of which is herein incorporated by reference. Similar techniques that exploit ionic interactions with the cell membrane to provoke the uptake of foreign nucleic acids include contacting a cell with a cationic polymer-nucleic acid complex. Exemplary cationic molecules that associate with polynucleotides so as to impart a positive charge favorable for interaction with the cell membrane are activated dendrimers (described, e.g., in Dennig (Topics in Current Chemistry 228:227, 2003), the disclosure of which is incorporated herein by reference) and diethylaminoethyl (DEAE)-dextran, the use of which as a transfection agent is described in detail, for example, in Gulick et al. (Curr. Protoc. in Mol. Biol. 40:1:9.2:9.2.1 , 1997), the disclosure of which is incorporated herein by reference. Magnetic beads are another tool that can be used to transfect a target cell in a mild and efficient manner, as this methodology utilizes an applied magnetic field in order to direct the uptake of nucleic acids. This technology is described in detail, for example, in US 2010 / 0227406, the disclosure of which is incorporated herein by reference.
[0232] Another useful tool for inducing the uptake of exogenous nucleic acids by a target cell is laserfection, a technique that involves exposing a cell to electromagnetic radiation of a particular wavelength in order to gently permeabilize the cell and allow polynucleotides to penetrate the cell membrane. This technique is described in detail, e.g., in Rhodes et al. (Methods in Cell Biology 82:309, 2007), the disclosure of which is incorporated herein by reference.
[0233] Microvesicles represent another potential vehicle that can be used to modify the genome of a target cell according to the methods described herein. For example, microvesicles that have been induced by the co-overexpression of the glycoprotein VSV-G with, e.g., a genome-modifying protein, such as a nuclease, can be used to efficiently deliver proteins into a cell that subsequently catalyze the sitespecific cleavage of an endogenous polynucleotide sequence so as to prepare the genome of the cell for the covalent incorporation of a polynucleotide of interest, such as a gene or regulatory sequence. The use of such vesicles, also referred to as Gesicles, for the genetic modification of eukaryotic cells is described in detail, e.g., in Mangion et al., Mol. Biotechnol. 64(3):278-292, 2022).
[0234] Pharmaceutical Compositions
[0235] The PAD3 or PAD3 inhibitor therapeutic agent of the present invention may serve as a therapeutic agent, e.g., an immunotherapy, in a pharmaceutical composition of the present invention. In some embodiments, the concentration of the PAD3 inhibitor therapeutic agent in the pharmaceutical composition is from 0.01 mg / mL to 200 mg / mL. The additional components of the pharmaceutical composition may improve bioavailability, half-life, efficacy, or reduce potential side-effects. Additional components may include, but are not limited to, compound(s) used to adjust the tonicity (e.g., render the composition hypertonic or hypotonic) or compound(s) for increasing or decreasing the mass or viscosity of the composition.
[0236] The composition may further include one or more additional pharmaceutically acceptable ingredients such as carriers, excipients, diluents, stabilizers, buffers, and the like, which may be incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in: Remington's Pharmaceutical Sciences (15th ed, Mack Publishing Company, Easton, PA (1975)), particularly Chapter 87 by Blaug, Seymour, therein. See also: Baldrick P. “Pharmaceutical excipient development: the need for preclinical guidance.” Regul. ToxicolPATENT
[0237] ATTORNEY DOCKET NO.: 51523-007WO2
[0238] Pharmacol. 32(2):210-8 (2000), Wang W. “Lyophilization and development of solid protein pharmaceuticals.” Int. J. Pharm. 203(1 -2):1 -60 (2000), Charman W N “Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts.” J Pharm Sci. 89(8):967-78 (2000), Powell et al. “Compendium of excipients for parenteral formulations” PDA J Pharm Sci Technol. 52:238-311 (1998) and the citations therein for additional information related to formulations.
[0239] An injectable pharmaceutical composition of the present invention may be ready for injection from a storage vial or reconstituted by adding sterile water to obtain a solution (e.g., from 1 mg / mL to 500 mg / mL). Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (when water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
[0240] In some embodiments, the PAD3 or PAD 3 inhibitor therapeutic agent is administered as part of a combination therapy (e.g., with chemotherapy, radiation therapy, or targeted therapy). The PAD3 or PAD 3 inhibitor therapeutic agent of the present invention may be administered simultaneously or sequentially with the other therapy. In some embodiments, the PAD3 inhibitor therapeutic agent is administered before the other therapeutic agent (e.g., within 1 week, within 6 days, within 5 days, within 4 days, within 3 days, within 2 days, within 1 day, or within 12 hours). In some embodiments, the PAD3 inhibitor therapeutic agent is administered after the other therapeutic agent (e.g., within 1 week, within 6 days, within 5 days, within 4 days, within 3 days, within 2 days, within 1 day, or within 12 hours). In some embodiments, the PAD3 or PAD3 inhibitor therapeutic agent and the other therapeutic are co-administered (e.g., concurrent therapy). In some embodiments, the additional therapeutic agent is formulated with the PAD3 or PAD3 inhibitor therapeutic agent (e.g., as described herein) prior to administration.
[0241] In some embodiments, the PAD3 or PAD3 inhibitor therapeutic agent may be formulated with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation (e.g., implants and microencapsulated delivery systems).
[0242] The pharmaceutical compositions can be included in a container, pack (e.g., blister pack), or dispenser together with instructions for administration.PATENT
[0243] ATTORNEY DOCKET NO.: 51523-007WO2
[0244] Dosing Regimen
[0245] In some embodiments, the treatment of the present invention is an injectable dosage form (e.g., parenteral administration, i.e., intravenous, intradermal, subcutaneous), an oral dosage form (e.g., a tablet or aerosol), or a topical dosage form (e.g., as a cream, gel, lotion, or ointment), wherein the PAD3 inhibitor (e.g., antibody, polypeptide, small molecule, or protein, each as describe herein) dose is from 0.0001 mg / kg to 500 mg / kg (e.g., from 0.1 mg / kg to 250 mg / kg, from 0.1 mg / kg to 100 mg / kg, or from 1 mg / kg to 20 mg / kg, or 1 mg / kg, 6 mg / kg, 10 mg / kg, 15 mg / kg, 20 mg / kg, 30 mg / kg, 40 mg / kg, 50 mg / kg, 60 mg / kg, 70 mg / kg, 80 mg / kg, 90 mg / kg, 100 mg / kg, 125 mg / kg, 150 mg / kg, 200 mg / kg, 250 mg / kg, 300 mg / kg, 350 mg / kg, 400 mg / kg, 450 mg / kg, 500 mg / kg), depending on subject age (e.g., a child age 6 to 11 , an adolescent age 12 to 18, or an adult at least 18 years old) and bodyweight (e.g., <84 kg, 84 kg, >84 kg). In some embodiments, the dose is administered as a single dose on a dosing schedule. In some embodiments, the dosing schedule can include administration at a frequency of once a day to once every six months. In other embodiments, the dosing schedule can include administration of a dose at least twice a day. In yet another embodiment, the dosing schedule can include a dose titration. In specific embodiments, the titration dosing schedule may include giving a higher dose for a period of time, e.g., day 1 or week 1 , followed by a lower dose for a period of time or the remainder of treatment. The higher dose may be achieved through a higher quantity of the therapeutic in a single dose or more frequent administration of doses. In other specific embodiments, the dosing schedule may include a lower initial dose for a period of time, e.g., day 1 or week 1 , followed by a higher dose for a period of time or the remainder of treatment. The lower dose may be achieved through a lower quantity of the therapeutic in a single dose or less frequent administration of doses. In some embodiments, the dose may be administered by intravenous infusion over a period of time greater than 1 minute (e.g., over 1 minute, over 5 minutes, over 10 minutes, over 15 minutes, over 25 minutes, over 30 minutes, over 35 minutes, over 40 minutes, over 45 minutes, over 50 minutes, over 55 minutes, or over 60 minutes).
[0246] Immune-driven Conditions
[0247] One aspect of the present invention features methods for treating immune-driven conditions. Exemplary conditions include inflammatory conditions such as asthma (e.g., aspirin sensitive / exacerbated asthma, atopic asthma, severe asthma, mild asthma, moderate to severe asthma, corticosteroid naive asthma, chronic asthma, corticosteroid resistant asthma, corticosteroid refractory asthma, newly diagnosed and untreated asthma, asthma due to smoking, asthma uncontrolled on corticosteroids, etc.), airway hyperreactivity, airway hyperresponsiveness, rhinosinusitis, rhinosinusitis with polyps, nasal polyposis, arthritis (e.g., osteoarthritis, rheumatoid arthritis, arthritic joints as a result of injury, etc.), seronegative enthesopathy and arthropathy (SEA) syndrome, osteoporosis, eosinophilic esophagitis, scleroderma, dermatitis, atopic dermatitis, allergic rhinitis, bullous pemphigoid, chronic urticaria, cartilage inflammation, polymyalgia rheumatic, polyarteritis nodossa, Wegener’s granulamatosis, Behcet’s disease, myelitis, polymyolitis, dermatomyolitis, dermatomyositis, vasculitis, arteritis, diabetic nephropathy, interstitial cystitis, graft versus host disease (GVHD), gastrointestinal inflammatory conditions (e.g., inflammatory bowel disease (IBD) , ulcerative colitis (UC), Crohn’s disease (CD), colitis (e.g., colitis caused by environmental insults (e.g., caused by or associated with a therapeutic regimen, such as chemotherapy, radiation therapy, etc.), infectious colitis, ischemic colitis, collagenous or lymphocyticPATENT
[0248] ATTORNEY DOCKET NO.: 51523-007WO2
[0249] colitis, necrotizing enterocolitis, colitis in conditions such as chronic granulomatous disease or celiac disease, food allergies, gastritis, infectious gastritis or enterocolitis (e.g., Helicobacter pylori- infected chronic active gastritis), and other forms of gastrointestinal inflammation caused by an infectious agent), and inflammatory pulmonary conditions (e.g., chronic obstructive pulmonary disease (COPD), infection-induced pulmonary conditions (including those associated with viral (e.g., influenza, parainfluenza, rotavirus, human metapneumovirus, and respiratory syncytial virus), bacterial, fungal (e.g., Aspergillus), parasitic, or prion infection, allergen-induced pulmonary conditions, pollutant-induced pulmonary conditions (e.g., asbestosis, silicosis, or berylliosis), gastric aspiration-induced pulmonary conditions, immune dysregulation, inflammatory conditions with genetic predisposition such as cystic fibrosis, physical trauma-induced pulmonary conditions (e.g., ventilator injury), emphysema, bronchitis, sarcoidosis, histiocytosis, lymphangiomyomatosis, acute lung injury, acute respiratory distress syndrome, chronic lung disease, bronchopulmonary dysplasia, pneumonia (e.g., community-acquired pneumonia, nosocomial pneumonia, ventilator-associated pneumonia, viral pneumonia, bacterial pneumonia, and severe pneumonia), airway exacerbations, and acute respiratory distress syndrome (ARDS)).
[0250] Exemplary conditions also include ocular conditions such as those relating to inflammatory disorders or autoimmune disorders. Exemplary ocular immune conditions include: uveitis, optic neuritis, keratitis, scleritis, vasculitis, vasospasm, immune-mediated demyelination, immune complex deposition, and hypercoagulability.
[0251] Exemplary conditions also include immune disorders such as those mediated at least in part by mast cells, such as asthma, eczema, itch, allergic rhinitis, allergic conjunctivitis, as well as autoimmune disorders including rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, pancreatitis, psoriasis, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, paraneoplastic autoimmune diseases, autoimmune hepatitis, bullous pemphigoid, myasthenia gravis, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, celiac disease, thyroiditis (e.g., Graves’ disease), Sjogren’s syndrome, Guillain-Barre disease, Raynaud’s phenomenon, Addison’s disease, liver diseases (e.g., primary biliary cirrhosis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis), and diabetes (e.g., type I diabetes).
[0252] ITIH4 Activity and Immunosuppression
[0253] Another aspect of the present invention includes the treatment of immune-driven conditions wherein the subject could benefit from suppression of the immune system (e.g., subjects who have an immune-driven condition that can be characterized by adverse immunoenhancement). The desired immunosuppressive response could be obtained by promoting ITIH4 activity in the subject. In the present invention, compositions that include a PAD3 inhibitor, e.g., as described herein, may be used to promote ITIH4 activity.
[0254] In one embodiment of the present invention, the treatment of an immune-driven condition includes administering compositions that include a PAD3 inhibitor to a subject that would benefit from immunosuppression, e.g., to reduce inflammation.
[0255] In other embodiments, the compositions that include a PAD3 inhibitor may be pharmaceutical composition for administration to a subject in need thereof.PATENT
[0256] ATTORNEY DOCKET NO.: 51523-007WO2
[0257] Subjects that have an immune-driven condition, where the immune-driven condition is characterized by adverse immunoenhancement, may be treated with compositions that include a PAD3 inhibitor. In some embodiments, the subject’s immune-driven condition is an autoimmune disease, endangered pregnancy, or rejection of a tissue, cell, graft, or organ transplant from a donor. In specific embodiments, the subject was administered compositions that include a PAD3 inhibitor (e.g., an antibody, peptide, small molecule, or protein as described herein) prior to, simultaneously with, or after tissue, cell, graft, or organ transplant. In other specific embodiments, the organ transplant can be a kidney transplant, a cornea transplant, a bone marrow transplant, a liver transplant, a lung transplant, or a heart transplant. In other embodiments, the subject’s immune-driven condition is either arthritis, allergy, asthma, pollinosis, or atopy. In other embodiments, the subject’s immune-driven condition is an autoimmune disease. In other embodiments, the subject’s immune-driven condition is a result of an adverse immune response to a separate therapeutic treatment.
[0258] Pregnancy
[0259] The ITIH4 activity is altered in a subject during the course of pregnancy. As this activity is related to immune function, the ITIH4 proteolytic activity has been observed to be enhanced in pregnant subjects in order to suppress the immune function to protect the fetus.
[0260] Another aspect of the present invention is a method for treating poor pregnancy health. As stated, if the ITIH4 activity is not increased appropriately to suppress the immune system, the fetus could be harmed. The poor pregnancy health resulting from an undesired immune response can be addressed by administering a composition that includes a PAD3 inhibitor, e.g., a small molecule or antibody as described herein, to prevent ITIH4 from deactivation via PAD3-mediated citrull ination in order to suppress immune function. In some embodiments, the treatment is administered until the desired immunosuppressive response is reached. In other embodiments, the treatment is administered for the entire pregnancy term.
[0261] ITIH4 and Immunoenhancement
[0262] Another aspect of the present invention includes the treatment of immune-driven conditions where the subject could benefit from enhancement of the immune system (e.g., subjects who have an immune-driven condition that can be characterized by adverse immunosuppression). In some embodiments, subjects with adverse immunosuppression include, but are not limited to, subjects with AIDS (or HIV positive), subjects with severe combined immune deficiency (SCID), diabetics, and those who are receiving chemotherapy for cancer, and those characterized as having a low white blood cell count. Immunocompromised subjects also include subjects with most forms of cancer (other than skin cancer), sickle cell anemia, cystic fibrosis, those who do not have a spleen, subjects with end stage kidney disease (dialysis), and those who have been taking corticosteroids on a frequent basis by pill or injection within the last year. Subjects with severe liver, lung, or heart disease also have adverse immunosuppression. The desired immunoenhancement response could be obtained by inhibiting ITIH4 proteolysis in the subject through the administration of an ITIH4 proteolysis inhibitor. In some embodiments, the ITIH4 proteolysis inhibitor is a therapeutic agent comprising PAD3 (e.g., as describedPATENT
[0263] ATTORNEY DOCKET NO.: 51523-007WO2
[0264] herein), such as PAD3 protein (e.g., at least 80% amino acid residues identical to SEQ ID No.: 1), a PAD3 derivative (e.g., a fragment or dimer), PAD3 mimic, an anti-PAD3 antibody, or PAD3 promoter.
[0265] Cancer
[0266] The complement system is considered an immune surveillance system against cancer. However, tumor cells develop inhibitory mechanisms to prevent CDC. Further, complement activation within the tumor environment can promote tumor growth, which may lead to side effects such as inflammation, immunosuppression, angiogenesis, and the initiation of other cancer-related signaling pathways.
[0267] One aspect of the present invention includes administration of a PAD3 therapeutic, e.g., PAD3 protein, a PAD3 protein derivative, a PAD3 protein mimic, an anti-PAD3 antibody, or a PAD3 protein promoter to increase the immune response in a subject with cancer. In some embodiments, PAD3 protein, PAD3 protein derivative, PAD3 protein mimic, or PAD3 protein promoter can be used in combination with current cancer therapies to enhance effectiveness.
[0268] Anti-Cancer Combination Therapies
[0269] The PAD3 therapeutic agent (e.g., a PAD3 protein, derivative thereof, or anti-PAD3 antibody as described herein) can also be administered as part of a combination therapy for the treatment of cancer. In the present invention, treating cancer with a combination therapy requires administering to a patient a therapeutically effective amount of: i) a PAD3 therapeutic (e.g., as described herein), and ii) an anticancer therapy (e.g., chemotherapy, target therapy, immunotherapy, hormonal therapy). In some embodiments, the PAD3 therapeutic agent is administered before the anticancer therapeutic agent (e.g., within 1 week, within 6 days, within 5 days, within 4 days, within 3 days, within 2 days, within 1 day, or within 12 hours). In some embodiments, the PAD3 therapeutic agent is administered after the anticancer therapeutic agent (e.g., within 1 week, within 6 days, within 5 days, within 4 days, within 3 days, within 2 days, within 1 day, or within 12 hours). In some embodiments, the PAD3 therapeutic agent and the anticancer therapeutic agent are co-administered (e.g., concurrent therapy). In some embodiments, the anticancer therapeutic agent is formulated with the PAD3 therapeutic agent prior to administration.
[0270] The anticancer therapy utilized in the combination therapy may be a cytotoxic chemotherapy agent such as an alkylating agent, a platinum-based compound, a antimetabolite, a antitumor antibiotic, or a plant alkaloid. Nonlimiting examples of alkylating agents include: cyclophosphamide (Cytoxan), infosfamide (Ifex), melphalan (Alkeran), chlorambucil (Leukeran), and bendamustine (Tranda, Bendeka). Nonlimiting examples of platinum-based compounds include: cisplatin, carboplatin, oxaliplatin (Eloxatin). Nonlimiting examples of antimetabolites include: methotrexate, 5-fluorouracil (5-FU), capecitabine (Xeloda), gemcitabine (Gemzar), pemetrexed (Alimta), cytarabine (ara-C), and 6-mercaptopurine (6-MP). Nonlimiting examples of antitumor antibiotics include: doxorubicin, daunorubicin, epirubicin, bleomycin, and mitomycin (Mutamycin). Nonlimiting examples of plant alkaloids include: vica alkaloids such as vincristine, vinblastine, and vinorelbind; taxanes such as paclitaxel (Taxol), docetaxel (Taxotere), and cabazitaxel (Jevtana); epipodophyllotoxins (Topoisomerase II inhibitors) such as etopside (VP-16); and camptothecins (Topoisomerase I inhibitors) such as irinotecan (Camptosar) and topotecan (Hycamtin).
[0271] The anticancer therapy utilized in the combination therapy may be a targeted therapy such as a tyrosine kinase inhibitor (TKI), a monoclonal antibody (mAb), or a antibody-drug conjugate (ADC).PATENT
[0272] ATTORNEY DOCKET NO.: 51523-007WO2
[0273] Nonlimiting examples of tyrosine kinase inhibitors include: imatinib (Gleevec), dasatinib (Sprycel), nilotinib (Tasigna), bosutinib (Bosulif), ponatinib (lolusig), erlotinib (Tarceva), gefitinib (Iressa), afatinib (Gilotrif), osimertinib (Tagrisso), sorafenib (Nexavar), sunitinib (Sutent), pazopanib (Votrient), axitinib (Inlyta), cabozantinib (Cabometyx), dabrafenib (Tafinlar), vemurafenib (Zelboraf), trametinib (Mekinist), cobimetinib (Cotellic), ruxolitinib (Jakafi), ibrutinib (Imbruvica), acalabrutinib (Calquence), idelalisib (Zydelig), and duvelisib (Copiktra). Nonlimiting examples of monoclonal antibodies include: rituximab (Rituxan), obinutuzumab (Gazyva), ofatumumab (Arzerra), trastuzumab (Herceptin), pertuzumab (Perjeta), cetuximab (Erbitux), panitumumab (Vectibix), bevacizumab (Avastin), daratumumab (Darzalex), isatuximab (Sarclisa), elotuzumab (Empliciti), and inotuzumab ozogamicin (Besponsa). Nonlimiting examples of antibody-drug conjugates include: T-DM1 / ado-trastuzumab emtansine (Kadcyla), brentuximab vedotin (Adcetris), sacituzumab govitecan (Trodelvy), and trastuzumab deruxtecan (Enhertu).
[0274] The anticancer therapy utilized in the combination therapy may be an immunotherapy such as an immune checkpoint inhibitor. Nonlimiting examples of immune checkpoint inhibitors include: anti-CTLA-4 such as ipilimumab (Yervoy); anti-PD-1 such as pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo); and anti-PD-L1 such as atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (bavencio).
[0275] The anticancer therapy utilized in the combination therapy may be a hormonal (endocrine_ therapy such as a selective estrogen receptor modulator (SERM), an aromatase inhibitor, a selective estrogen receptor degrader (SERD), a anti-androgen, or a GnRH (LHRH) agonist or antagonist.
[0276] Nonlimiting examples of SERM include: tamoxifen. Nonlimiting examples of aromatase inhibitors include: anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin). Nonlimiting examples of SERD include: fulvestrant (Faslodex). Nonlimiting examples of anti-androgens include: bicalutamide (Casodex), flutamide, nilutamide, enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa).
[0277] Nonlimiting examples of GnRH (LHRH) agonists include: leuprolide (Lupron) and goserelin (Zoladex). Non limiting examples of GnRH (LHRH) antagonists include: degarelix (Firmagon) and Relugolix (Orgovyx).
[0278] Other anticancer therapy agents that may be utilized in the combination therapy include, but are not limited to: lenalidomide (Revlimid), thalidomide (Thalomid), pomalidomide (Pomalyst), bortezomib (Velcade), carfilzomib (Kyprolis), ixazomib (Ninlaro), venetoclax (Venclexta), olaparib (Lynparza), rucaparib (Rubraca), niraparib (Zejula), talazoparib (Talzenna), everolimus (Afinitor), temsirolimus (Torisel), arsenic trioxide (Trisenox), all-trans retinoic acid (ATRA), trabectedin (Yondelis), L-asparaginase (Elspar, Erwinia asparaginase, Pegaspargase), and selinexor (Xpovio).
[0279] Examples
[0280] Methods
[0281] Samples
[0282] From a panel of 10 pregnant donors, 30 plasma samples obtained during Terms 1 (1-13 weeks), 2 (20-24 weeks), and / or 3 (>35 weeks) of pregnancy were purchased from in.vent Diagnostica GmbHPATENT
[0283] ATTORNEY DOCKET NO.: 51523-007WO2
[0284] (Henningsdorf, Germany). Control samples included 20 plasma samples from non-pregnant women. All samples were purchased from in.vent Diagnostica GmbH (Germany).
[0285] The pregnant donors age range was 30 - 39 years, while the control samples age range was 20-70 years. All biospecimens were certified to have been collected under a clinical study that has been reviewed by an institutional / lndependent Review Board (IRB) in accordance with the requirements of local governing regulatory agencies.
[0286] A total of 50 human plasma samples (K3EDTA) from patients with advanced-stage ovarian cancer (11 samples), as well as lung (13 samples), renal(15 samples), prostate (20 samples), and pancreatic cancer (14 samples), were purchased from PRECISION for medicine (Norton, MA, USA). Further, 4 serum samples from healthy donors and 4 serum samples from patients with renal cancer were also purchased from PRECISION for medicine (Norton, MA, USA).
[0287] All biospecimens were certified to have been collected under a clinical study that has been reviewed by an IRB (Protocol #PFM064, Advarra IRB, Columbia, MD, USA) in accordance with the requirements of local governing regulatory agencies, including the DHHS and FDA Codes of Federal Regulations, on the Protection of Human Subjects (45 CFR Part 46 and 21 CFR Part 56, respectively).
[0288] Metabolomics
[0289] For metabolomics evaluation, samples were thawed on ice and 75 pL of pre-cooled isoelectric precipitation (ISP) solution (CLINMASS® Steroids in Plasma LC-MS / MS Complete Kit (RECIPE Chemicals + Instruments GmbH, Munich, Germany)) was added to 50 pL of plasma, after which the mixture was vortexed for 30 seconds. The ISP solution contains six steroids in its panel, d7-androstenedione, d4- cortisol, d5- DHEAS, d5-11 -deoxycortisol, d8-17-hydroxyprogesterone, and d3-testosterone, as internal standards. The sample was then left for 10 min before being centrifuged at 14,000 rpm for 10 min at 4 °C, after which the supernatant was collected. 40 pL of supernatant was subjected to metabolite analysis on a SCIEX X500R UPLC-QTOF / mass spectrometry (MS) system.
[0290] High-performance liquid chromatography (HPLC) separation was performed using the SCIEX ExionLC AC system on a Phenomenex: Luna® Omega 3 m Polar C18 100A column. Data was collected on a SCIEX X500R QTOF mass spectrometer with SCIEX OS software: TOF - MS survey scan with Information Dependent Acquisition (IDA) - triggering of up to 16 product ion scans. Data processing was also performed in SCIEX OS software with simultaneous identification and quantification being accomplished in single software (all devices from AB SCIEX, Framingham, U.S.A.).
[0291] Of each sample, 40 pL was injected for chromatography separation at 30 °C, with a flow rate of 0.8 mL / min, 0.1% formic acid and 2 mM ammonium formate in HPLC water as mobile phase A and HPLC acetonitrile and methanol (50:50) plus 0.1% formic acid and 2 mM ammonium formate as mobile phase B. A 26-min linear gradient was set as follows: 0 min: 2% B, 0-1 min: 2% B, 1-16 min: 98% B, 16-20 min: 98% B.
[0292] The SCIEX X500R QTOF system with a TURBO V™ source and capable of electrospray ionization (ESI) was used in positive polarity. The ion source temperature was set to 500aC and the ion source voltage to 5500 V. An information dependent acquisition (IDA) method, consisting of a TOF-MS survey (250-1100 Da for 350 msec) was used. The declustering potential (DP) was set to 80V. ThePATENT
[0293] ATTORNEY DOCKET NO.: 51523-007WO2
[0294] collision energy (CE) was set to 10 eV with a collision energy spread (CES) of ± 0 eV. To achieve the most complete MS / MS coverage, the dynamic background subtraction (DBS) function was activated.
[0295] Data processing of metabolomics data
[0296] MARKERVIEW™ Software 1.3 (SCIEX) was used to process, align, deconvolute, and normalize (sum of total area) the obtained raw data in which the retention time (RT) was from 0.5 min to 26 min. Mass and RT tolerance values were set to 10 ppm and 0.15 minutes. Mass and RT of internal standards used for analysis include: d7-androstenedione, d4- cortisol, d5- DHEAS, d5-11 -deoxycortisol, d8-17-hydroxyprogesterone, and d3-testosterone introduced via the ISP mixture during sample preparation.
[0297] Principal component analysis (PCA) was used to visualize system stability of the system and sample distribution. The orthogonal partial least squares discriminant analysis (OPLS-DA) was used to identify the variables responsible for the discrimination.
[0298] A list of the intensities for each detected peak was generated, using retention time and the mass-to-charge (m / z) ratio data pairs as the parameters for each ion. Manual scanning of the 10,000 spectral features represented by a unique m / z, retention time, and peak area allowed for generation of a list of 670 peaks of interest used for further evaluation. The Formula Finder algorithm was used to identify potential differential metabolites and generate a group of probable formulas on an unknown ion based on the secondary fragment information, mass error, and isotope distribution patterns.
[0299] Western blot analysis
[0300] Non-pregnant and pregnant (Term 3) plasma samples were subjected to SDS-PAGE using 4 to 12% Bis-Tris Plus Wedgewell Precast Midi Protein Gels and transferred to nitrocellulose membranes using the iBolt 2 PVDF mini stacks semidry Transfer System (Invitrogen). The membranes were blocked by incubation in BioRad EveryBlot Blocking buffer (Cat# 12010020) for 1 hour before addition of the antibodies, which were diluted in BioRad EveryBlot Blocking buffer (Cat# 12010020, BioRad, LOCATION). Detection of human ITIH4 was achieved either using a monoclonal HRP-conjugated mouse anti-ITIH4 antibody (0.2 pg / ml; sc-515353HRP, Santa Cruz, LOCATION), specific for C-terminal fragments of ITIH4, or a sheep polyclonal anti-ITI H4 antibody (0.1 pg / mL; AF8167, RD systems). PAD3 was detected using a rabbit recombinant monoclonal anti-PAD3 antibody (1 pg / mL) (ab172959, Abeam, Waltham, USA); His tagged proteins were detected using an HRP-conjugated monoclonal mouse anti-His antibody (0.2 pg / ml)(MAB050H, R&D Systems, Minneapolis, USA). The secondary antibody, used for detection of non-conjugated primary antibodies was a species-specific HRP-conjugated anti-IgG antibody (ProteinSimple), selected based on the host species of the primary antibody. The Western enhanced chemiluminescence (ECL) substrate (BioRad) and the Invitrogen iBright Imaging System were used to visualize and image the bands.
[0301] Activation of ITIH4-His in plasma
[0302] To assess the activation (cleavage) of ITIH4 in pregnant and cancer plasma samples, ITIH4-His (2 pg / mL, Cat. No. 10259-IT, R&D Systems) was incubated at 37°C with 10 pL of selected plasma in 30 pL of GVB (Ca and Mg) buffer (Cat. No. B120, Complement Technology). The reaction was initiated, and PAD inhibitors were added during the activation step to evaluate their effects on the activation orPATENT
[0303] ATTORNEY DOCKET NO.: 51523-007WO2
[0304] inhibition of ITIH4-His. The PAD inhibitors include: Compound 30 (also known as C1 -amidine (Cat. No.
[0305] 506282, Sigma-Aldrich)), Compound 31 (also known as GSK484 (Cat. No. SML1658, Sigma-Aldrich)), Compound 32 (also known as GSK199 (Cat. no. 40866, Cayman Chemical)), Compound 33 (also known as CAY10723 (Cat. no. 38018, Cayman Chemical)), and Compound 1 (also known as CAY10727 (Cat. no. 26543, Cayman Chemical)). Foreach, 2 pL from a 100 pg / mL stock was used. After the activation step, the reaction was stopped by diluting the sample in SDS-PAGE loading buffer.
[0306] Band intensity was analyzed using the Invitrogen iBright Imaging System.
[0307] Example 1: PAD3 and ITIH4 Activity Relationship
[0308] A screening of the influence of ITIH4 activity in the presence of different PAD inhibitors was
[0309] performed. The PAD3 inhibitor, Compound
[0310]
[0311] was found to be particularly effective at inhibiting the activity of ITIH4 (Figs. 1 A and 1 B).
[0312] Additionally, ITIH4 activity is postulated to be increased during pregnancy in order to suppress immune response for the health of the fetus. A screen of serum from nonpregnant subjects compared to pregnant subjects revealed an increased presence of PAD3 in the serum of nonpregnant subjects (Fig.
[0313] 2). This supports the hypothesis that PAD3 is correlated with the deactivation pathway of ITIH4 allowing for immunoenhancement.
[0314] The activation of ITIH4-H is by screening inhibitors of PAD proteins using plasma from nonpregnant women was assessed. ITI H4-His was added to each sample and 5 different compounds known to inhibit citrull ination were assessed (Figs. 1 A and 1 B). Compound 30 (also known as C1 -amidine) and Compound 1 (also known as CAY10727) were found to activate ITIH4-his in the non-pregnant samples. Compound 30 serves as a general PAD inhibitor, while Compound 1 is a specific inhibitor of PAD3. It was found that PAD3 inhibition using various doses of Compound 1 and Compound 30 activates ITIH4-His in non-pregnant samples (Fig. 1 C). These data suggest that inhibition of PAD3 activates ITIH4 in the plasma of non-pregnant females. This suggests that modulation of PAD3 activity regulates ITIH4 activity, which may be one of the mechanisms underlying maternal immune tolerance and immune adaptation during gestation, acting as a checkpoint for maternal immune surveillance.
[0315] PAD3-mediated citrullination regulates ITIH4: pharmacologic PAD inhibition alters citrullination and promotes ITIH4 activation. Functionally, PAD3 inhibition modulates immune surveillance, dampens complement pathway output, and shifts toward tolerance. These findings motivate a two-tier model of immune control — a tolerance set point and an autoimmune activation threshold — both tuned by post-translational modification (PTM). Without being bound to theory, we propose that this PTM operates as a post-translational immune checkpoint essential for maternal-fetal adaptation, with dynamic regulation of ITIH4 activation during pregnancy serving both as a readout of checkpoint activity and as a contributor to immune tolerance.
[0316] Based on these findings, the effects of the PAD inhibitor C1 -amidine on complement pathwayPATENT
[0317] ATTORNEY DOCKET NO.: 51523-007WO2
[0318] activity was also assessed (Fig. 3). It was observed that this citrul lination inhibitor reduces activity of all three complement pathways in an ITIH4-dependent manner.
[0319] Example 2: PAD3 and cancer
[0320] Numerous types of cancer, e.g., the types of cancers described herein, can be characterized as producing immunosuppressive responses. Subjects in need of a treatment for a cancer susceptible to treatment with an immunotherapy are candidates for treatment with a PAD3 therapeutic, e.g., PAD3 protein and derivatives thereof such as fragments, fusion proteins, and dimers, or an anti-PAD3 antibody. The PAD3 therapeutic could be formulated for solution infusion for subjects with a cancer susceptible to treatment with an immunotherapy.
[0321] The PAD3 therapeutics are screened in serum from subjects with a cancer susceptible to treatment with an immunotherapy to evaluate their influence on ITIH4 activity and on enhancing immune function in subjects with different types of cancer.
[0322] Enumerated Embodiments
[0323] E1 . A method of suppressing the immune response in a subject with an immune-driven condition, the method comprising administering a PAD3 selective inhibitor of formula (I):
[0324]
[0325] or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a PAD3 selective inhibitor of formula (I),
[0326] wherein,
[0327] n is 0, 1 , 2, 3, or 4;
[0328] X is Cl or F;
[0329] Rk >\
[0330] TI
[0331] 1 i 1
[0332] Y is H, C1-C3 alkyl, or R2, where = is either a single bond or a double bond; each Z1, Z2, and Z3are independently OR1, NR1, O,
[0333]
[0334] ,
[0335] each R1is independently H, C1-C3 alkyl, halogen, -NHC(O)-R4, -C(O)NHz, =0, optionally substituted 6- to 9 -membered C5-C7 heteroaryl, or two R1together with the atoms to which they are bound form an optionally substituted 5- to 6-memeberred C2-C5 heterocyclyl or optionally substituted 5- to 6-membered C2-C5 heteroaryl;
[0336] R2is H, C1-C3 alkyl, O, or Ce aryl;
[0337] R3is H, C1-C3 alkyl, C6aryl,
[0338]
[0339] R2and R3together with the atoms to which they are attached combine to form a Ce aryl or a 6- to 10-membered C5-C7 heteroaryl;PATENT
[0340] ATTORNEY DOCKET NO.: 51523-007WO2
[0341]
[0342] each R5is independently -O-(Ci-C3 alkyl), -CO2H, or halogen; or
[0343] two R5together with the atoms to which they are attached form an optionally substituted 5- to 6-membered heterocyclyl;
[0344] L is bond or -C(O)NH-; and
[0345] each optionally substituted group is optionally substituted with 1 , 2, 3, or 4 substituents independently selected from a group consisting of: C1-C3 alkyl, -O-(Ci-C3 alkyl), halogen, and =0. E2. A method of suppressing the immune response in a subject with an immune-driven condition, the method comprising administering a PAD3 selective inhibitor selected from Table 1 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a PAD3 selective inhibitor selected from Table 1 or a pharmaceutically acceptable salt thereof.
[0346] E3. The method of embodiment E1 or E2, wherein the PAD3 selective inhibitor is Compound 1 or Compound 2.
[0347] E4. The method of embodiment E1 or E2, wherein the PAD3 selective inhibitor is Compound 30. E5. The method of any one of embodiments E1 to E3, wherein the PAD3 selective inhibitor is Compound 1 .
[0348] E6. A method of suppressing the immune response in a subject with an immune-driven condition, the method comprising administering an anti-PAD3 antibody.
[0349] E7. The method of any one of the aforementioned embodiments, wherein the immune-driven condition is inflammation.
[0350] E8. The method of any one of the aforementioned embodiments, wherein the immune-driven condition is an autoimmune disease.
[0351] E9. The method of any one of the aforementioned embodiments, wherein the immune-driven condition is rheumatoid arthritis.
[0352] E10. The method of any one of the aforementioned embodiments, wherein the immune-driven condition is an ocular condition.
[0353] E11 . The method of any one of the aforementioned embodiments, wherein the immune-driven condition is the rejection of a tissue, cell, graft, or organ transplant from a donor by a recipient human subject in need thereof.
[0354] E12. The method of embodiment E11 , the method comprising administering prior to, simultaneously with, or after tissue, cell, graft, or organ transplantation.
[0355] E13. The method of embodiment E11 or E12, wherein the organ transplant is a kidney transplant, a cornea transplant, a bone marrow transplant, a liver transplant, a lung transplant, or a heart transplant. E14. The method of any one of the aforementioned embodiments, wherein the immune-driven condition is an adverse immune response resulting from administration of a therapeutic agent.
[0356] E15. A method of improving pregnancy health of a subject, the method comprising administering PAD3 inhibitor or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising a PAD3 inhibitor or a pharmaceutically acceptable salt thereof, to the subject in need thereof.PATENT
[0357] ATTORNEY DOCKET NO.: 51523-007WO2
[0358] E16. The method of Embodiment E15, wherein the method comprises administering for the entire term of the pregnancy.
[0359] E17. The method of embodiments E15 or E16, wherein the PAD3 selective inhibitor is a compound selected from Table 1 , or a pharmaceutically acceptable salt thereof.
[0360] E18. The method of any one of embodiments E15 to E17, wherein the PAD3 selective inhibitor is Compound 1 , Compound 2, Compound 30, or a pharmaceutically acceptable salt thereof.
[0361] E19. The method of any one of embodiments E15 to E18, wherein the PAD3 selective inhibitor is Compound 1 , or a pharmaceutically acceptable salt thereof.
[0362] E20. The method of any one of embodiments E15 to E17, wherein the PAD3 selective inhibitor is Compound 1 , or a pharmaceutically acceptable salt thereof.
[0363] E21. The method of any one of the aforementioned embodiments, wherein the pharmaceutical composition comprising the PAD3 inhibitor or pharmaceutically acceptable salt thereof is administered to the subject in need thereof.
[0364] E22. The method of embodiment E21 , wherein the pharmaceutical composition is formulated for injection, oral administration, or topical administration.
[0365] E23. A method of enhancing the immune response in a subject with an immune driven condition characterized by immunosuppression, the method comprising administering to the subject a therapeutic agent comprising PAD3 protein, or a derivative thereof, or an anti-PAD3 antibody.
[0366] E24. The method of embodiment E23, wherein the therapeutic agent comprises an amino acid sequence at least 80% identical to PAD3.
[0367] E25. The method of embodiment E23 or E24, wherein the immune driven condition is a cancer susceptible to treatment with an immunotherapy.
[0368] E26. The method of embodiment E25, wherein the cancer is a solid tumor cancer.
[0369] E27. The method of embodiment E25 or E26, wherein the cancer is melanoma, renal cell carcinoma (RCC), colorectal cancer, Metastatic colorectal cancer, Gl malignancies, hepatocellular carcinoma (HOC), HNSCC, Malignant Pleural Mesothelioma, bladder cancer, sarcoma, osteosarcoma, Kaposi’s sarcoma, soft tissue sarcoma, lymphoma, mantle cell, follicular, small lymphocytic, B-cell malignancies, anaplastic large cell lymphoma, Merkel cell carcinoma, MSI-high cancer, gastric cancer, gastroesophageal cancer, cervical cancer, PMBCL, endometrial carcinoma, esophagus cancer, cutaneous squamous-cell carcinoma, breast cancer, Metastatic breast cancer, TMB-high cancer, SCLC, basal cell carcinoma, multiple myeloma, testicular cancer, pancreatic cancer, prostate cancer, ovarian cancer, thyroid cancer, leukemia, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia, acute promyelocytic leukemia (APL), head and neck cancers, lung cancer, non-small cell lung cancer (NSCLC), melanoma, gastrointestinal stromal tumors (GIST), solid tumors, malignant pleural mesothelioma, myelofibrosis, polycythemia vera, Waldenstrom’s macroglobulinemia, glioblastoma, urothelial carcinoma, or myelodysplastic syndromes (MDS).
[0370] E28. The method of any one of the aforementioned embodiments, wherein the method comprises administering to the subject a combination therapy comprising: a) the therapeutic agent comprising PAD3 protein, or derivative thereof, or an anti-PAD3 antibody, and b) an additional anticancer therapy, each in an amount that together is effective for the treatment of cancer.
[0371] E29. The method of embodiment E28, wherein the additional anticancer therapy is a chemotherapy.PATENT
[0372] ATTORNEY DOCKET NO.: 51523-007WO2
[0373] E30. The method of embodiment E29, wherein the chemotherapy is a cytotoxic chemotherapy agent selected from: an alkylating agent, a platinum-based compound, a antimetabolite, a antitumor antibiotic, or a plant alkaloid.
[0374] E31. The method of embodiment E30, wherein the cytotoxic chemotherapy agent is selected from a group consisting of: cyclophosphamide (Cytoxan), infosfamide (Ifex), melphalan (Alkeran), chlorambucil (Leukeran), bendamustine (Tranda, Bendeka), cisplatin, carboplatin, oxaliplatin (Eloxatin), methotrexate, 5-fluorouracil (5-FU), capecitabine (Xeloda), gemcitabine (Gemzar), pemetrexed (Alimta), cytarabine (ara-C), and 6-mercaptopurine (6-MP), doxorubicin, daunorubicin, epirubicin, bleomycin, and mitomycin (Mutamycin), vincristine, vinblastine, vinorelbind, paclitaxel (Taxol), docetaxel (Taxotere), cabazitaxel (Jevtana), etopside (VP-16), camptothecins, irinotecan (Camptosar), and topotecan (Hycamtin).
[0375] E32. The method of embodiment E28, wherein the additional anticancer therapy is a targeted therapy. E33. The method of embodiment E32, wherein the targeted therapy is a tyrosine kinase inhibitor (TKI), a monoclonal antibody (mAb), or an antibody-drug conjugate (ADC).
[0376] E34. The method of embodiment E32 or E33, wherein the targeted therapy is selected from a group consisting of: imatinib (Gleevec), dasatinib (Sprycel), nilotinib (Tasigna), bosutinib (Bosulif), ponatinib (Iclusig), erlotinib (Tarceva), gefitinib (Iressa), afatinib (Gilotrif), osimertinib (Tagrisso), sorafenib (Nexavar), sunitinib (Sutent), pazopanib (Votrient), axitinib (Inlyta), cabozantinib (Cabometyx), dabrafenib (Tafinlar), vemurafenib (Zelboraf), trametinib (Mekinist), cobimetinib (Cotellic), ruxolitinib (Jakafi), ibrutinib (Imbruvica), acalabrutinib (Calquence), idelalisib (Zydelig), duvelisib (Copiktra), rituximab (Rituxan), obinutuzumab (Gazyva), ofatumumab (Arzerra), trastuzumab (Herceptin), pertuzumab (Perjeta), cetuximab (Erbitux), panitumumab (Vectibix), bevacizumab (Avastin), daratumumab (Darzalex), isatuximab (Sarclisa), elotuzumab (Empliciti), inotuzumab ozogamicin (Besponsa), T-DM1 / ado-trastuzumab emtansine (Kadcyla), brentuximab vedotin (Adcetris), sacituzumab govitecan (Trodelvy), and trastuzumab deruxtecan (Enhertu).
[0377] E35. The method of embodiment E28, wherein the additional anticancer therapy is an immunotherapy. E36. The method of embodiment E35, wherein the immunotherapy is an immune checkpoint inhibitor. E37. The method of embodiment E36, wherein the immune checkpoint inhibitor is anti-CTLA-4, anti- PD-1 , or anti-PDpL1.
[0378] E38. The method of any one of embodiments E35 to E37, wherein the immunotherapy is selected from a group consisting of: ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo), atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (bavencio).
[0379] E39. The method of embodiment E28, wherein the additional anticancer therapy is a hormonal therapy.
[0380] E40. The method of embodiment E39, wherein the hormonal therapy is a selective estrogen receptor modulator (SERM), an aromatase inhibitor, a selective estrogen receptor degrader (SERD), an antiandrogen, a GnRH (LHRH) agonist, or a GnRH (LHRH) antagonist.
[0381] E41. The method of embodiment E39 or E40, wherein the hormonal therapy is selected from a group consisting of: tamoxifen, anastrozole (Arimidex), letrozole (Femara), exemestane (Aromasin), fulvestrant (Faslodex), bicalutamide (Casodex), flutamide, nilutamide, enzalutamide (Xtandi), apalutamide (Erleada), darolutamide (Nubeqa), leuprolide (Lupron), goserelin (Zoladex), degarelix (Firmagon), and Relugolix (Orgovyx).PATENT
[0382] ATTORNEY DOCKET NO.: 51523-007WO2
[0383] E42. The method of embodiment E28, wherein the additional anticancer therapy is selected from a group consisting of: lenalidomide (Revlimid), thalidomide (Thalomid), pomalidomide (Pomalyst), bortezomib (Velcade), carfilzomib (Kyprolis), ixazomib (Ninlaro), venetoclax (Venclexta), olaparib (Lynparza), rucaparib (Rubraca), niraparib (Zejula), talazoparib (Talzenna), everolimus (Afinitor), temsirolimus (Torisel), arsenic trioxide (Trisenox), all-trans retinoic acid (ATRA), trabectedin (Yondelis), L-asparaginase (Elspar, Erwinia asparaginase, Pegaspargase), and selinexor (Xpovio).
[0384] E43. The method of any one of embodiments E28 to E42, wherein the administration of the combination therapy comprises administering the PAD3 therapeutic agent and the additional anticancer therapy simultaneously.
[0385] E44. The method of embodiment E43, wherein the PAD3 therapeutic agent and the additional anticancer therapy are formulated and administered together.
[0386] E45. The method of any one embodiment E28 to E42, wherein the administration of the combination therapy comprises administering the PAD3 therapeutic agent and the additional anticancer therapy sequentially.
[0387] E46. The method of embodiment E45, wherein the sequential administration comprises administering the PAD3 therapeutic agent and administering the additional anticancer therapy within one week of each other.
[0388] E47. The method of embodiment E45 or E46, wherein the sequential administration comprises administering the therapeutic of embodiment E24 and administering the additional anticancer therapy within 24 hours of each other.
[0389] E48. The method of any one of embodiments E45 to E47, wherein the therapeutic of embodiment E24 is administered before the additional anticancer agent.
[0390] E49. The method of any one of embodiments E45 to E47, wherein the therapeutic of embodiment E24 is administered after the additional anticancer agent.
[0391] E50. The method of any one of embodiments E23 to E49, wherein the PAD3 therapeutic agent administered is a gene therapy encoding the PAD3 protein.
[0392] E51. The method of embodiment E50, wherein the gene therapy is administered to the subject via a viral vector.
[0393] E52. The method of embodiment E50, wherein the gene therapy comprises a polynucleotide encoding the PAD3 protein is incorporated into recombinant AAV (rAAV) vector.PATENT
[0394] ATTORNEY DOCKET NO.: 51523-007WO2
[0395] E53. A method of treating an immune-driven condition comprising reducing the activity of at least one specific complement pathway of the complement system (e.g., classical, lectin, or alternative complement pathway) by administering a PAD3 inhibitor.
[0396] E54. The method of embodiment E53, wherein the PAD3 inhibitor is of formula (I), (la), (II), or a compound of Table 1.
[0397] E55. The method of embodiment E54, wherein the PAD3 inhibitor is a gene therapy encoding the PAD3 protein.
[0398] E56. The method of any one of embodiments E53 to E55, wherein the method comprises reducing the activity of all three complement pathways.
[0399] E57. The method of embodiment 56, wherein administration of the PAD3 inhibitor reduces the activity of all three specific complement pathways (e.g., classical, lectin, and alternative complement pathway).
[0400] Other Embodiments
[0401] While the invention has been described with reference to specific embodiments, it will be understood that numerous modifications are possible. This application is intended to encompass all variations, uses, and adaptations of the invention that follow the general principles described herein, as well as departures that are customary or routine in the relevant art. Such variations may be applied to the essential features set forth above and are considered to fall within the scope of the claims. Other embodiments are within the claims.
Claims
PATENTATTORNEY DOCKET NO.: 51523-007WO2What is claimed is:CLAIMS1 . A method of suppressing the immune response in a subject with an immune-driven condition, the method comprising administering a PAD3 selective inhibitor of formula (la):or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a PAD3 selective inhibitor of formula (I),wherein,n is 0, 1 , 2, 3, or 4;R3x / \TI1 i 1Y is H, C1-C3 alkyl, or R2, where = is either a single bond or a double bond; each Z1, Z2, and Z3are independently CR1, NR1, O,each R1is independently H, C1-C3 alkyl, halogen, -NHC(O)-R4, -C(O)NH2, =0, 6- to 9 -membered C5-C7 heteroaryl, or two R1together with the atoms to which they are bound form an optionally substituted 5- to 6-memeberred C2-C5 heterocyclyl or optionally substituted 5- to 6-membered C2- C5 heteroaryl;R2is H, C1-C3 alkyl, O, or Ce aryl;R3is H, C1-C3 alkyl, C6aryl,R2and R3together with the atoms to which they are attached combine to form a Ce aryl or a 6- to 10-membered C5-C7 heteroaryl;each R5is independently -O-(Ci-C3 alkyl), -CO2H, or halogen;L is bond or -C(O)NH-; andeach optionally substituted group is optionally substituted with 1 , 2, 3, or 4 substituents independently selected from a group consisting of: C1-C3 alkyl, -O-(Ci-C3 alkyl), halogen, and =0.
2. A method of suppressing the immune response in a subject with an immune-driven condition, the method comprising administering a PAD3 selective inhibitor selected from Table 1 , or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a PAD3 selective inhibitor selected from Table 1 , or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 or 2, wherein the PAD3 selective inhibitor is Compound 1 ..PATENTATTORNEY DOCKET NO.: 51523-007WO24. A method of suppressing the immune response in a subject with an immune-driven condition, the method comprising administering a anti-PAD3 antibody.
5. The method of any one of claims 1 to 4, wherein the immune-driven condition is selected from a group consisting of: inflammation, an autoimmune disease, rheumatoid arthritis, an ocular condition, or an adverse immune response resulting from administration of a therapeutic agent.
6. The method of any one of claims 1 to 4, wherein the immune-driven condition is the rejection of a tissue, cell, graft, or organ transplant from a donor by a recipient human subject in need thereof.
7. The method of claim 6, the method comprising administering prior to, simultaneously with, or after tissue, cell, graft, or organ transplantation.
8. The method of claim 6, wherein the organ transplant is a kidney transplant, a cornea transplant, a bone marrow transplant, a liver transplant, a lung transplant, or a heart transplant.
9. A method of improving pregnancy health of a subject, the method comprising administering PAD3 inhibitor or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising a PAD3 inhibitor or a pharmaceutically acceptable salt thereof, to the subject in need thereof.
10. The method of claim 9, wherein the method comprises administering for the entire term of the pregnancy.
11. The method of claim 9 or 10, wherein the PAD3 selective inhibitor is a compound selected from Table 1 , or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 , wherein the PAD3 selective inhibitor is Compound 1.
13. The method of any one of claims 1 to 12, wherein the pharmaceutical composition comprising the PAD3 inhibitor or pharmaceutically acceptable salt thereof is administered to the subject in need thereof.
14. The method of claim 13, wherein the pharmaceutical composition is formulated for injection, oral administration, or topical administration.
15. A method of enhancing the immune response in a subject with an immune driven condition characterized by immunosuppression, the method comprising administering to the subject a therapeutic agent comprising PAD3 protein, or a derivative thereof, or an anti-PAD3 antibody.
16. The method of claim 15, wherein the therapeutic agent comprises an amino acid sequence at least 80% identical to PAD3.PATENTATTORNEY DOCKET NO.: 51523-007WO217. The method of claim 15 or 16, wherein the immune driven condition is a cancer susceptible to treatment with an immunotherapy.
18. The method of claim 17, wherein the cancer is a solid tumor cancer.
19. The method of claim 17 or 18, wherein the cancer is melanoma, renal cell carcinoma (RCC), colorectal cancer, Metastatic colorectal cancer, Gl malignancies, hepatocellular carcinoma (HOC), HNSCC, Malignant Pleural Mesothelioma, bladder cancer, sarcoma, osteosarcoma, Kaposi’s sarcoma, soft tissue sarcoma, lymphoma, mantle cell, follicular, small lymphocytic, B-cell malignancies, anaplastic large cell lymphoma, Merkel cell carcinoma, MSI-high cancer, gastric cancer, gastroesophageal cancer, cervical cancer, PMBCL, endometrial carcinoma, esophagus cancer, cutaneous squamous-cell carcinoma, breast cancer, Metastatic breast cancer, TMB-high cancer, SCLC, basal cell carcinoma, multiple myeloma, testicular cancer, pancreatic cancer, prostate cancer, ovarian cancer, thyroid cancer, leukemia, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia, acute promyelocytic leukemia (APL), head and neck cancers, lung cancer, non-small cell lung cancer (NSCLC), melanoma, gastrointestinal stromal tumors (GIST), solid tumors, malignant pleural mesothelioma, myelofibrosis, polycythemia vera, Waldenstrom’s macroglobulinemia, glioblastoma, urothelial carcinoma, or myelodysplastic syndromes (MDS).
20. The method of any one of claims 15 to 19, wherein the method comprises administering to the subject a combination therapy comprising: a) the therapeutic agent comprising PAD3 protein, or derivative thereof, or an anti-PAD3 antibody, and b) an additional anticancer therapy, each in an amount that together is effective for the treatment of cancer.
21. The method of claim 20, wherein the additional anticancer therapy is a chemotherapy, a targeted therapy, an immunotherapy, or a hormonal therapy.
22. The method of claim 20, wherein the additional anticancer therapy is selected from a group consisting of: lenalidomide (Revlimid), thalidomide (Thalomid), pomalidomide (Pomalyst), bortezomib (Velcade), carfilzomib (Kyprolis), ixazomib (Ninlaro), venetoclax (Venclexta), olaparib (Lynparza), rucaparib (Rubraca), niraparib (Zejula), talazoparib (Talzenna), everolimus (Afinitor), temsirolimus (Torisel), arsenic trioxide (Trisenox), all-trans retinoic acid (ATRA), trabectedin (Yondelis), L-asparaginase (Elspar, Erwinia asparaginase, Pegaspargase), and selinexor (Xpovio).
23. The method of any one of claims 20 to 22, wherein the administration of the combination therapy comprises administering the PAD3 therapeutic agent and the additional anticancer therapy simultaneously.
24. The method of any one of claims 20 to 22, wherein the administration of the combination therapy comprises administering the PAD3 therapeutic agent and the additional anticancer therapy sequentially.PATENTATTORNEY DOCKET NO.: 51523-007WO225. The method of claim 24, wherein the sequential administration comprises administering the PAD3 therapeutic agent and administering the additional anticancer therapy within one week of each other.
26. The method of claim 24 or 25, wherein the sequential administration comprises administering the therapeutic of claim 16 and administering the additional anticancer therapy within 24 hours of each other.
27. The method of any one of claims 24 to 26, wherein the therapeutic of claim 16 is administered before the additional anticancer agent.
28. The method of any one of claims 24 to 26, wherein the therapeutic of claim 16 is administered after the additional anticancer agent.
29. The method of any one of claims 15 to 28, wherein the PAD3 therapeutic agent administered is a gene therapy encoding the PAD3 protein.
30. The method of claim 29, wherein the gene therapy is administered to the subject via a viral vector.
31. The method of claim 29, wherein the gene therapy comprises a polynucleotide encoding the PAD3 protein is incorporated into recombinant AAV (rAAV) vector.
